<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Warfarin</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Coumadin">
  <link href="../-/s/css_modules/mediawiki.action.view.redirectPage.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/mediawiki.action.view.redirectPage.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Warfarin</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Warfarin</b>, sold under the brand name <b>Coumadin</b> among others,<span class="mw-ref" id="cite_ref-brands_1-1"><a href="#cite_note-brands-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> is a medication that is used as an anticoagulant (blood thinner).<span class="mw-ref" id="cite_ref-AHFS2017_5-0"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people who have atrial fibrillation, valvular heart disease or artificial heart valves.<span class="mw-ref" id="cite_ref-AHFS2017_5-1"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Less commonly it is used following ST-segment elevation myocardial infarction (STEMI) and orthopedic surgery.<span class="mw-ref" id="cite_ref-AHFS2017_5-2"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> It is generally taken by mouth, but may also be used by injection into a vein.<span class="mw-ref" id="cite_ref-AHFS2017_5-3"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>



<div role="note" class="hatnote navigation-not-searchable">This article is about the anticoagulation medication. For the rodenticide often called "coumarins", see <a href="4-Hydroxycoumarins.htm" tppabs="https://ptable.com/wiki/compounds/A/4-hydroxycoumarins" title="4-hydroxycoumarins" class="mw-redirect">4-hydroxycoumarins</a>.</div>
<p>

</p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Warfarin</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Warfarin.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Warfarin.svg.png" data-file-width="512" data-file-height="378" data-file-type="drawing" height="148" width="200"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Warfarin_ball-and-stick_model.png" tppabs="https://ptable.com/wiki/compounds/I/m/Warfarin_ball-and-stick_model.png" data-file-width="2093" data-file-height="1501" data-file-type="bitmap" height="143" width="200"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˈ</span><span>w</span><span>ɔːr</span><span>f</span><span>ər</span><span>ɪ</span><span>n</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Coumadin, others<span class="mw-ref" id="cite_ref-brands_1-0"><a href="#cite_note-brands-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/warfarin-sodium.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/warfarin-sodium.html'" tppabs="https://www.drugs.com/monograph/warfarin-sodium.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a682277.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a682277.html'" tppabs="https://medlineplus.gov/druginfo/meds/a682277.html" class="external text external">a682277</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Warfarin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Warfarin'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Warfarin" class="external text external">Warfarin</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Warfarin&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Warfarin&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Warfarin&SearchType=BasicSearch" class="external text external">Warfarin</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_2-0"><a href="#cite_note-Drugs.com_pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_2-1"><a href="#cite_note-Drugs.com_pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li></ul>

<ul><li>Contraindicated<span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_2-2"><a href="#cite_note-Drugs.com_pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth or intravenous</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>B01AA03<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=B01AA03  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=B01AA03'" tppabs="https://www.whocc.no/atc_ddd_index/?code=B01AA03" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span> ℞-only<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>79–100% (by mouth)<span class="mw-ref" id="cite_ref-PCK_3-0"><a href="#cite_note-PCK-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>99%<span class="mw-ref" id="cite_ref-TGA_4-0"><a href="#cite_note-TGA-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver: CYP2C9, 2C19, 2C8, 2C18, 1A2 and 3A4<span class="mw-ref" id="cite_ref-TGA_4-1"><a href="#cite_note-TGA-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>1 week (active half-life is 20-60 hours)<span class="mw-ref" id="cite_ref-TGA_4-2"><a href="#cite_note-TGA-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Kidney (92%)<span class="mw-ref" id="cite_ref-TGA_4-3"><a href="#cite_note-TGA-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(<i>RS</i>)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)- 2<i>H</i>-chromen-2-one</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=81-81-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=81-81-2'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=81-81-2" class="external text external">81-81-2</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/54678486  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/54678486'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/54678486" class="external text external">54678486</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6853  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6853'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6853" class="external text external">6853</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00682  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00682'" tppabs="https://www.drugbank.ca/drugs/DB00682" class="external text external">DB00682</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.10442445.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.10442445.html'" tppabs="http://www.chemspider.com/Chemical-Structure.10442445.html" class="external text external">10442445</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=5Q7ZVV76EI  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=5Q7ZVV76EI'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=5Q7ZVV76EI" class="external text external">5Q7ZVV76EI</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D08682  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D08682'" tppabs="https://www.kegg.jp/entry/D08682" class="external text external">D08682</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10033  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10033'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10033" class="external text external">CHEBI:10033</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1464  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1464'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1464" class="external text external">ChEMBL1464</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID5023742  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID5023742'" tppabs="https://comptox.epa.gov/dashboard/DTXSID5023742" class="external text external">DTXSID5023742</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.001.253  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.001.253'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.001.253" class="external text external">100.001.253</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>19</sub><span>H</span><sub>16</sub><span>O</span><sub>4</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">308.333</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28%3DO%29CC%28C%5C1%3DC%28%2FO%29c2ccccc2OC%2F1%3DO%29c3ccccc3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28%3DO%29CC%28C%5C1%3DC%28%2FO%29c2ccccc2OC%2F1%3DO%29c3ccccc3'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28%3DO%29CC%28C%5C1%3DC%28%2FO%29c2ccccc2OC%2F1%3DO%29c3ccccc3" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC(=O)CC(C\1=C(/O)c2ccccc2OC/1=O)c3ccccc3</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:PJVWKTKQMONHTI-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=460939157&page2=Warfarin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=460939157&page2=Warfarin'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=460939157&page2=Warfarin" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>The common side effect is bleeding.<span class="mw-ref" id="cite_ref-AHFS2017_5-4"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Less common side effects may include areas of tissue damage and purple toes syndrome.<span class="mw-ref" id="cite_ref-AHFS2017_5-5"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Use is not recommended during pregnancy.<span class="mw-ref" id="cite_ref-AHFS2017_5-6"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> It is recommended that the effects of warfarin typically be monitored by checking prothrombin time (INR) every one to four weeks.<span class="mw-ref" id="cite_ref-AHFS2017_5-7"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Many other medications and dietary factors can interact with warfarin, either increasing or decreasing its effectiveness.<span class="mw-ref" id="cite_ref-AHFS2017_5-8"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Ag2012_6-0"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The effects of warfarin may be reversed with phytomenadione (vitamin K<sub>1</sub>), fresh frozen plasma, or prothrombin complex concentrate.<span class="mw-ref" id="cite_ref-Ag2012_6-1"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


<p>Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K<sub>1</sub>.<span class="mw-ref" id="cite_ref-Ag2012_6-2"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Without sufficient active vitamin K<sub>1</sub>, clotting factors II, VII, IX, and X have decreased clotting ability.<span class="mw-ref" id="cite_ref-Ag2012_6-3"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The anticlotting protein C and protein S are also inhibited, but to a lesser degree.<span class="mw-ref" id="cite_ref-Ag2012_6-4"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> A few days are required for full effect to occur, and these effects can last for up to five days.<span class="mw-ref" id="cite_ref-AHFS2017_5-9"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


<p>Warfarin first came into commercial use in 1948 as a rat poison.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> In 1954 it was approved for medical use in the United States.<span class="mw-ref" id="cite_ref-AHFS2017_5-10"><a href="#cite_note-AHFS2017-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_9-0"><a href="#cite_note-WHO21st-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Warfarin is available as a generic medication.<span class="mw-ref" id="cite_ref-BNF69_10-0"><a href="#cite_note-BNF69-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span>  In 2017, it was the 51st most commonly prescribed medication in the United States, with more than 15 million prescriptions.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Warfarin is used to decrease the tendency for thrombosis, or as secondary prophylaxis (prevention of further episodes) in those individuals who have already formed a blood clot (thrombus). Warfarin treatment can help prevent formation of future blood clots and help reduce the risk of embolism (migration of a thrombus to a spot where it blocks blood supply to a vital organ).<span class="mw-ref" id="cite_ref-AHFS_13-0"><a href="#cite_note-AHFS-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>Warfarin is best suited for anticoagulation (clot formation inhibition) in areas of slowly running blood (such as in veins and the pooled blood behind artificial and natural valves), and in blood pooled in dysfunctional cardiac atria. Thus, common clinical indications for warfarin use are atrial fibrillation, the presence of artificial heart valves, deep venous thrombosis, and pulmonary embolism (where the embolized clots first form in veins). Warfarin is also used in antiphospholipid syndrome. It has been used occasionally after heart attacks (myocardial infarctions), but is far less effective at preventing new thromboses in coronary arteries. Prevention of clotting in arteries is usually undertaken with antiplatelet drugs, which act by a different mechanism from warfarin (which normally has no effect on platelet function).<span class="mw-ref" id="cite_ref-Hirsh_2003_14-0"><a href="#cite_note-Hirsh_2003-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> It can be used to treat people following ischemic strokes due to atrial fibrillation, though direct oral anticoagulants (DOACs) may offer greater benefits.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Dosing">Dosing</h3></summary>
    
<p>Dosing of warfarin is complicated because it is known to interact with many commonly used medications and <a href="Vitamin_K.htm#Food_sources" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_K#Food_sources" title="Vitamin K">certain foods</a>.<span class="mw-ref" id="cite_ref-Holbrook2005_16-0"><a href="#cite_note-Holbrook2005-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> These interactions may enhance or reduce warfarin's anticoagulation effect. To optimize the therapeutic effect without risking dangerous side effects such as bleeding, close monitoring of the degree of anticoagulation is required by a blood test measuring an INR.  During the initial stage of treatment, INR is checked daily; intervals between tests can be lengthened if the patient manages stable therapeutic INR levels on an unchanged warfarin dose.<span class="mw-ref" id="cite_ref-Hirsh_2003_14-1"><a href="#cite_note-Hirsh_2003-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Newer point-of-care testing is available and has increased the ease of INR testing in the outpatient setting. Instead of a blood draw, the point of care test involves a simple finger prick.<span class="mw-ref" id="cite_ref-Perry_2010_17-0"><a href="#cite_note-Perry_2010-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>When initiating warfarin therapy ("warfarinization"), the doctor will decide how strong the anticoagulant therapy needs to be. The target INR level varies from case to case depending on the clinical indicators, but tends to be 2–3 in most conditions. In particular, target INR may be 2.5–3.5 (or even 3.0–4.5) in patients with one or more mechanical heart valves.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>In addition, for the first three days of "warfarinization", the levels of protein C and protein S (anticoagulation factors) drop faster than procoagulation proteins such as factor II, VII, IX, and X. Therefore, bridging anticoagulant therapies (usually <a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">heparin</a>) are often used to reverse this temporary hypercoagulable state.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Maintenance_dose">Maintenance dose</h4></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Theuraputic_window.png" tppabs="https://ptable.com/wiki/compounds/I/m/Theuraputic_window.png" data-file-width="380" data-file-height="271" data-file-type="bitmap" height="157" width="220"><div class="thumbcaption" style="text-align: left">Vitamin K1-warfarin interaction effect. When warfarin levels are high, people have more risk of bleeding. Conversely, lower levels of warfarin lead to increased risk of blood clots. There is a narrow range where the benefits of warfarin are greater than the risks, its therapeutic window. Certain drugs, herbal medicines, and foods can interact with warfarin, increasing or decreasing a previously stable warfarin level.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></div></div></div>
<p>Recommendations by many national bodies, including the American College of Chest Physicians,<span class="mw-ref" id="cite_ref-Holbrook2012_20-0"><a href="#cite_note-Holbrook2012-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> have been distilled to help manage dose adjustments.<span class="mw-ref" id="cite_ref-pmid15926414_21-0"><a href="#cite_note-pmid15926414-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>The maintenance dose of warfarin can fluctuate significantly depending on the amount of <a href="Vitamin_K.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_K" title="Vitamin K">vitamin K</a><sub>1</sub> in the diet. Keeping vitamin K<sub>1</sub> intake at a stable level can prevent these fluctuations. Leafy green vegetables tend to contain higher amounts of vitamin K<sub>1</sub>. Green parts of members of the family Apiaceae, such as parsley, cilantro, and dill are extremely rich sources of vitamin K; cruciferous vegetables such as cabbage and broccoli, as well as the darker varieties of lettuces and other leafy greens, are also relatively high in vitamin K<sub>1</sub>. Green vegetables such a peas and green beans do not have such high amounts of vitamin K<sub>1</sub> as leafy greens. Certain vegetable oils have high amounts of vitamin K<sub>1</sub>.  Foods low in vitamin K<sub>1</sub> include roots, bulbs, tubers, and most fruits and fruit juices. Cereals, grains, and other milled products are also low in vitamin K<sub>1</sub>.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Self-testing">Self-testing</h4></summary>
    
<p>
Patients are making increasing use of self-testing and home monitoring of oral anticoagulation. International guidelines on home testing were published in 2005.<span class="mw-ref" id="cite_ref-Ansell2005_23-0"><a href="#cite_note-Ansell2005-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> The guidelines stated: </p><blockquote><p>"The consensus agrees that patient self-testing and patient self-management are effective methods of monitoring oral anticoagulation therapy, providing outcomes at least as good as, and possibly better than, those achieved with an anticoagulation clinic. All patients must be appropriately selected and trained. Currently available self-testing/self-management devices give INR results that are comparable with those obtained in laboratory testing."<span class="mw-ref" id="cite_ref-Ansell2005_23-1"><a href="#cite_note-Ansell2005-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p></blockquote><p> A 2006 systematic review and meta-analysis of 14 randomized trials showed home testing led to a reduced incidence of complications (thrombosis and major bleeding), and improved the time in the therapeutic range.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Alternative_anticoagulants">Alternative anticoagulants</h3></summary>
    
<p>In some countries, other <a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">coumarins</a> are used instead of warfarin, such as <a href="Acenocoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Acenocoumarol" title="Acenocoumarol">acenocoumarol</a> and <a href="Phenprocoumon.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenprocoumon" title="Phenprocoumon">phenprocoumon</a>. These have a shorter (acenocoumarol) or longer (phenprocoumon) half-life, and are not completely interchangeable with warfarin. Several types of anticoagulant drugs offering the efficacy of warfarin without a need for monitoring, such as dabigatran, apixaban, edoxaban, and rivaroxaban, have been approved in a number of countries for classical warfarin uses. Complementing these drugs are reversal agents available for dabigatran (idarucizumab), and for apixaban, and rivaroxaban (andexanet alfa).<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> Andexanet alfa is suggested for edoxaban, but use of it is considered off label due to limited evidence. A reversal agent for dabigatran, apixaban, edoxaban, and revaroxaban is in development (Ciraparantag).<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>All anticoagulants are generally contraindicated in situations in which the reduction in clotting that they cause might lead to serious and potentially life-threatening bleeds. This includes people with active bleeding conditions (such as gastrointestinal ulcers), or disease states with increased risk of bleeding (e.g., low platelets, severe liver disease, uncontrolled hypertension). For patients undergoing surgery, treatment with anticoagulants is generally suspended. Similarly, spinal or lumbar puncture (e.g., spinal injections, epidurals, etc.) carry increased risk so treatment is suspended prior to these procedures.<span class="mw-ref" id="cite_ref-martindale_27-0"><a href="#cite_note-martindale-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-FDA2015_28-0"><a href="#cite_note-FDA2015-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>Warfarin should not be given to people with heparin-induced thrombocytopenia until platelet count has improved or normalised.<span class="mw-ref" id="cite_ref-martindale_27-1"><a href="#cite_note-martindale-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Warfarin is usually best avoided in people with protein C or protein S deficiency as these thrombophilic conditions increase the risk of skin necrosis, which is a rare but serious side effect associated with warfarin.<span class="mw-ref" id="cite_ref-rapini_29-0"><a href="#cite_note-rapini-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pregnancy">Pregnancy</h3></summary>
    

<p>Warfarin is contraindicated in pregnancy, as it passes through the placental barrier and may cause bleeding in the fetus; warfarin use during pregnancy is commonly associated with spontaneous abortion, stillbirth, neonatal death, and preterm birth.<span class="mw-ref" id="cite_ref-HDT_30-0"><a href="#cite_note-HDT-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> Coumarins (such as warfarin) are also teratogens, that is, they cause birth defects; the incidence of birth defects in infants exposed to warfarin <i>in utero</i> appears to be around 5%, although higher figures (up to 30%) have been reported in some studies.<span class="mw-ref" id="cite_ref-Loftus_31-0"><a href="#cite_note-Loftus-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> Depending on when exposure occurs during pregnancy, two distinct combinations of congenital abnormalities can arise.<span class="mw-ref" id="cite_ref-HDT_30-1"><a href="#cite_note-HDT-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="First_trimester_of_pregnancy">First trimester of pregnancy</h4></summary>
    
<p>Usually, warfarin is avoided in the first trimester, and a low molecular weight heparin such as <a href="Enoxaparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Enoxaparin" title="Enoxaparin" class="mw-redirect">enoxaparin</a> is substituted. With heparin, risk of maternal haemorrhage and other complications are still increased, but heparins do not cross the placental barrier, so do not cause birth defects.<span class="mw-ref" id="cite_ref-Loftus_31-1"><a href="#cite_note-Loftus-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> Various solutions exist for the time around delivery.</p>

<p>When warfarin (or another 4-hydroxycoumarin derivative) is given during the first trimester—particularly between the sixth and ninth weeks of pregnancy—a constellation of birth defects known variously as fetal warfarin syndrome (FWS), warfarin embryopathy, or coumarin embryopathy can occur. FWS is characterized mainly by skeletal abnormalities, which include nasal hypoplasia, a depressed or narrowed nasal bridge, scoliosis, and calcifications in the vertebral column, femur, and heel bone, which show a peculiar stippled appearance on X-rays. Limb abnormalities, such as brachydactyly (unusually short fingers and toes) or underdeveloped extremities, can also occur.<span class="mw-ref" id="cite_ref-HDT_30-2"><a href="#cite_note-HDT-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-Loftus_31-2"><a href="#cite_note-Loftus-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> Common nonskeletal features of FWS include low birth weight and developmental disabilities.<span class="mw-ref" id="cite_ref-HDT_30-3"><a href="#cite_note-HDT-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-Loftus_31-3"><a href="#cite_note-Loftus-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Second_trimester_and_later">Second trimester and later</h4></summary>
    
<p>Warfarin administration in the second and third trimesters is much less commonly associated with birth defects, and when they do occur, are considerably different from fetal warfarin syndrome. The most common congenital abnormalities associated with warfarin use in late pregnancy are central nervous system disorders, including spasticity and seizures, and eye defects.<span class="mw-ref" id="cite_ref-HDT_30-4"><a href="#cite_note-HDT-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-Loftus_31-4"><a href="#cite_note-Loftus-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> Because of such later pregnancy birth defects, anticoagulation with warfarin poses a problem in pregnant women requiring warfarin for vital indications, such as stroke prevention in those with artificial heart valves.</p>

<p>According to the American College of Chest Physicians (ACCP), warfarin may be used in lactating women who wish to breast-feed their infants.<span class="mw-ref" id="cite_ref-Bates_2012_32-0"><a href="#cite_note-Bates_2012-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> Available data does not suggest that warfarin crosses into the breast milk. Similarly, INR levels should be checked to avoid adverse effects.<span class="mw-ref" id="cite_ref-Bates_2012_32-1"><a href="#cite_note-Bates_2012-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Bleeding">Bleeding</h3></summary>
    
<p>The only common side effect of warfarin is bleeding. The risk of severe bleeding is small but definite (a typical yearly rate of 1–3% has been reported),<span class="mw-ref" id="cite_ref-Holbrook2012_20-1"><a href="#cite_note-Holbrook2012-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> and any benefit needs to outweigh this risk when warfarin is considered. All types of bleeding occur more commonly, but the most severe ones are those involving the brain (intracerebral hemorrhage/hemorrhagic stroke) and the spinal cord.<span class="mw-ref" id="cite_ref-Holbrook2012_20-2"><a href="#cite_note-Holbrook2012-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Risk of bleeding is increased if the INR is out of range (due to accidental or deliberate overdose or due to interactions).<span class="mw-ref" id="cite_ref-Garcia2010_33-0"><a href="#cite_note-Garcia2010-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> This risk increases greatly once the INR exceeds 4.5.<span class="mw-ref" id="cite_ref-Brown2015_34-0"><a href="#cite_note-Brown2015-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>

<p>A number of risk scores exist to predict bleeding in people using warfarin and similar anticoagulants. A commonly used score (HAS-BLED) includes known predictors of warfarin-related bleeding: uncontrolled high blood pressure (H), abnormal kidney function (A), previous stroke (S), known previous bleeding condition (B), previous labile INR when on anticoagulation (L), elderly as defined by age over 65 (E), and drugs associated with bleeding (e.g., aspirin) or alcohol misuse (D). While their use is recommended in clinical practice guidelines,<span class="mw-ref" id="cite_ref-Camm2012_35-0"><a href="#cite_note-Camm2012-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> they are only moderately effective in predicting bleeding risk and do not perform well in predicting hemorrhagic stroke.<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> Bleeding risk may be increased in people on hemodialysis.<span class="mw-ref" id="cite_ref-pmid17720522_37-0"><a href="#cite_note-pmid17720522-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> Another score used to assess bleeding risk on anticoagulation, specifically Warfarin or Coumadin, is the ATRIA score, which uses a weighted additive scale of clinical findings to determine bleeding risk stratification.<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> The risks of bleeding are increased further when warfarin is combined with antiplatelet drugs such as <a href="Clopidogrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Clopidogrel" title="Clopidogrel">clopidogrel</a>, <a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">aspirin</a>, or nonsteroidal anti-inflammatory drugs.<span class="mw-ref" id="cite_ref-pmid17698822_39-0"><a href="#cite_note-pmid17698822-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Warfarin_necrosis">Warfarin necrosis</h3></summary>
    

<p>A rare but serious complication resulting from treatment with warfarin is warfarin necrosis, which occurs more frequently shortly after commencing treatment in patients with a deficiency of protein C. Protein C is an innate anticoagulant that, like the procoagulant factors that warfarin inhibits, requires vitamin K-dependent carboxylation for its activity. Since warfarin initially decreases protein C levels faster than the coagulation factors, it can paradoxically increase the blood's tendency to coagulate when treatment is first begun (many patients when starting on warfarin are given <a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">heparin</a> in parallel to combat this), leading to massive thrombosis with skin necrosis and gangrene of limbs. Its natural counterpart, purpura fulminans, occurs in children who are homozygous for certain protein C mutations.<span class="mw-ref" id="cite_ref-pmid10718793_40-0"><a href="#cite_note-pmid10718793-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Osteoporosis">Osteoporosis</h3></summary>
    
<p>After initial reports that warfarin could reduce bone mineral density, several studies demonstrated a link between warfarin use and osteoporosis-related fracture. A 1999 study in 572 women taking warfarin for deep venous thrombosis, risk of vertebral fracture and rib fracture was increased; other fracture types did not occur more commonly.<span class="mw-ref" id="cite_ref-pmid10448778_41-0"><a href="#cite_note-pmid10448778-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> A 2002 study looking at a randomly selected selection of 1,523 patients with osteoporotic fracture found no increased exposure to anticoagulants compared to controls, and neither did stratification of the duration of anticoagulation reveal a trend towards fracture.<span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>

<p>A 2006 retrospective study of 14,564 Medicare recipients showed that warfarin use for more than one year was linked with a 60% increased risk of osteoporosis-related fracture in men; there was no association in women. The mechanism was thought to be a combination of reduced intake of vitamin K (a vitamin necessary for bone health) and inhibition by warfarin of vitamin K-mediated carboxylation of certain bone proteins, rendering them nonfunctional.<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Purple_toe_syndrome">Purple toe syndrome</h3></summary>
    

<p>Another rare complication that may occur early during warfarin treatment (usually within 3 to 8 weeks of commencement) is <i>purple toe syndrome</i>. This condition is thought to result from small deposits of <a href="Cholesterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cholesterol" title="Cholesterol">cholesterol</a> breaking loose and causing embolisms in blood vessels in the skin of the feet, which causes a blueish-purple colour and may be painful.<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>

<p>It is typically thought to affect the big toe, but it affects other parts of the feet as well, including the bottom of the foot (plantar surface). The occurrence of purple toe syndrome may require discontinuation of warfarin.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Calcification">Calcification</h3></summary>
    
<p>Several studies have also implicated warfarin use in valvular and vascular calcification. No specific treatment is available, but some modalities are under investigation.<span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>
The major side effect of warfarin use is bleeding. Risk of bleeding is increased if the INR is out of range (due to accidental or deliberate overdose or due to interactions).<span class="mw-ref" id="cite_ref-Garcia2010_33-1"><a href="#cite_note-Garcia2010-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> Many drug interactions can increase the effect of warfarin, also causing an overdose.<span class="mw-ref" id="cite_ref-Holbrook2005_16-1"><a href="#cite_note-Holbrook2005-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>For people who need rapid reversal of warfarin – such as due to serious bleeding – or who need emergency surgery, the effects of warfarin can be reversed with <a href="Vitamin_K.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_K" title="Vitamin K">vitamin K</a>, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP).<span class="mw-ref" id="cite_ref-Ag2012_6-5"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Generally, 4-factor PCC can be given more quickly than FFP, the amount needed is a smaller volume of fluid than FFP, and does not require ABO blood typing. Administration of PCCs result in rapid hemostasis, similar to that of FFP; namely, with comparable rates of thromboembolic events, but with reduced rates of volume overload. Blood products should not be routinely used to reverse warfarin overdose, when vitamin K could work alone.<span class="mw-ref" id="cite_ref-Ag2012_6-6"><a href="#cite_note-Ag2012-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> While PCC has been found in lab tests to be better than FFP, when rapid reversal is needed,<span class="mw-ref" id="cite_ref-Chai2016_47-0"><a href="#cite_note-Chai2016-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span> as of 2018, it was unclear whether there is a difference in outcomes such as death or disability.<span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>

<p>Details on reversing warfarin are provided in clinical practice guidelines from the American College of Chest Physicians.<span class="mw-ref" id="cite_ref-Ansell_49-0"><a href="#cite_note-Ansell-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> For people with an international normalized ratio (INR) between 4.5 and 10.0, a small dose (about 1000 mcg = one milligram) of oral vitamin K is sufficient. When warfarin is being given and INR is in therapeutic range, simple discontinuation of the drug for five days is usually enough to reverse the effect and cause INR to drop below 1.5.<span class="mw-ref" id="cite_ref-pmid12186515_50-0"><a href="#cite_note-pmid12186515-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    

<p>Warfarin interacts with many commonly used drugs, and the metabolism of warfarin varies greatly between patients.<span class="mw-ref" id="cite_ref-Holbrook2005_16-2"><a href="#cite_note-Holbrook2005-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Some foods have also been reported to interact with warfarin.<span class="mw-ref" id="cite_ref-Holbrook2005_16-3"><a href="#cite_note-Holbrook2005-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Apart from the metabolic interactions, highly protein bound drugs can displace warfarin from <a href="Serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serum_albumin" title="Serum albumin">serum albumin</a> and cause an increase in the INR.<span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> This makes finding the correct dosage difficult, and accentuates the need of monitoring; when initiating a medication that is known to interact with warfarin (e.g., <a href="Simvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Simvastatin" title="Simvastatin">simvastatin</a>), INR checks are increased or dosages adjusted until a new ideal dosage is found.</p>

<p>When taken with nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin increases the risk for gastrointestinal bleeding. This increased risk is due to the anti-platelet effect of NSAIDs as well as the possible damage to the gastrointestinal mucosa.<span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>

<p>Many commonly used antibiotics, such as <a href="Metronidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Metronidazole" title="Metronidazole">metronidazole</a> or the macrolides, will greatly increase the effect of warfarin by reducing the metabolism of warfarin in the body. Other broad-spectrum antibiotics can reduce the amount of the normal bacterial flora in the bowel, which make significant quantities of vitamin K<sub>1</sub>, thus potentiating the effect of warfarin.<span class="mw-ref" id="cite_ref-Juurlink_53-0"><a href="#cite_note-Juurlink-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> In addition, food that contains large quantities of vitamin K<sub>1</sub> will reduce the warfarin effect.<span class="mw-ref" id="cite_ref-Holbrook2005_16-4"><a href="#cite_note-Holbrook2005-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-Holbrook2012_20-3"><a href="#cite_note-Holbrook2012-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Thyroid activity also appears to influence warfarin dosing requirements;<span class="mw-ref" id="cite_ref-Kurnik_54-0"><a href="#cite_note-Kurnik-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> hypothyroidism (decreased thyroid function) makes people less responsive to warfarin treatment,<span class="mw-ref" id="cite_ref-55"><a href="#cite_note-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> while hyperthyroidism (overactive thyroid) boosts the anticoagulant effect.<span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> Several mechanisms have been proposed for this effect, including changes in the rate of breakdown of clotting factors and changes in the metabolism of warfarin.<span class="mw-ref" id="cite_ref-Kurnik_54-1"><a href="#cite_note-Kurnik-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span><span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></p>

<p>Excessive use of alcohol is also known to affect the metabolism of warfarin and can elevate the INR and thus increase the risk of bleeding.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span> The U.S. Food and Drug Administration (FDA) product insert on warfarin states that alcohol should be avoided.<span class="mw-ref" id="cite_ref-TGA_4-4"><a href="#cite_note-TGA-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> The Cleveland Clinic suggests that when taking warfarin one should not drink more than "one beer, 6 oz of wine, or one shot of alcohol per day".<span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></p>

<p>Warfarin also interacts with many herbs and spices,<span class="mw-ref" id="cite_ref-drug-herb_60-0"><a href="#cite_note-drug-herb-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span> some used in food (such as <a href="Ginger.htm" tppabs="https://ptable.com/wiki/compounds/A/Ginger" title="Ginger">ginger</a> and garlic) and others used purely for medicinal purposes (such as ginseng and <i>Ginkgo biloba</i>). All may increase bleeding and bruising in people taking warfarin; similar effects have been reported with borage (starflower) oil.<span class="mw-ref" id="cite_ref-61"><a href="#cite_note-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span> St. John's Wort, sometimes recommended to help with mild to moderate depression, reduces the effectiveness of a given dose of warfarin; it induces the enzymes that break down warfarin in the body, causing a reduced anticoagulant effect.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span></p>

<p>Between 2003 and 2004, the UK Committee on Safety of Medicines received several reports of increased INR and risk of haemorrhage in people taking warfarin and cranberry juice.<span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-Suvarna_64-0"><a href="#cite_note-Suvarna-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-Aston_65-0"><a href="#cite_note-Aston-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> Data establishing a causal relationship is still lacking, and a 2006 review found no cases of this interaction reported to the FDA;<span class="mw-ref" id="cite_ref-Aston_65-1"><a href="#cite_note-Aston-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> nevertheless, several authors have recommended that both doctors and patients be made aware of its possibility.<span class="mw-ref" id="cite_ref-Pham_66-0"><a href="#cite_note-Pham-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span> The mechanism behind the interaction is still unclear.<span class="mw-ref" id="cite_ref-Aston_65-2"><a href="#cite_note-Aston-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:302px"><img src="../I/m/Warfarin_tautomers.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Warfarin_tautomers.svg.png" data-file-width="512" data-file-height="157" data-file-type="drawing" height="92" width="300"><div class="thumbcaption" style="text-align: left">Acyclic tautomer <i>(left)</i> and cyclic hemiketal tautomer <i>(right)</i></div></div></div>
<p>X-ray crystallographic studies of warfarin show that it exists in tautomeric form, as the cyclic <a href="Hemiacetal.htm" tppabs="https://ptable.com/wiki/compounds/A/Hemiketal" title="Hemiketal" class="mw-redirect">hemiketal</a>, which is formed from the 4-hydroxycoumarin and the ketone in the 3-position substituent.<span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> However, the existence of many 4-hydroxycoumadin anticoagulants (for example <a href="Phenprocoumon.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenprocoumon" title="Phenprocoumon">phenprocoumon</a>) that possess no ketone group in the 3-substituent to form such a structure, suggests that the hemiketal must tautomerise to the 4-hydroxy form in order for warfarin to be active.<span class="mw-ref" id="cite_ref-pmid17691835_68-0"><a href="#cite_note-pmid17691835-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Stereochemistry">Stereochemistry</h3></summary>
    
<p>Warfarin contains a stereocenter and consists of two enantiomers. This is a racemate, i.e., a 1: 1 mixture of (<i> R </i>) – and the (<i> S </i>) – form:<span class="mw-ref" id="cite_ref-Rote_Liste_69-0"><a href="#cite_note-Rote_Liste-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>
<table class="wikitable" style="text-align:center">
<tbody><tr class="hintergrundfarbe6">
<th colspan="2">Enantiomers of warfarin</th></tr>
<tr>
<td><figure-inline><img src="../I/m/(R)-Warfarin_Structural_Formula_V1.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/(R)-Warfarin_Structural_Formula_V1.svg.png" data-file-width="364" data-file-height="258" data-file-type="drawing" height="142" width="200"></figure-inline><br><small> CAS Number: 5543-58-8</small></td>
<td><figure-inline><img src="../I/m/(S)-Warfarin_Structural_Formula_V1.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/(S)-Warfarin_Structural_Formula_V1.svg.png" data-file-width="364" data-file-height="258" data-file-type="drawing" height="142" width="200"></figure-inline><br><small> CAS Number: 5543-57-7</small></td></tr>
</tbody></table>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Warfarintablets5-3-1.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Warfarintablets5-3-1.jpg" data-file-width="800" data-file-height="496" data-file-type="bitmap" height="136" width="220"><div class="thumbcaption" style="text-align: left">3<span>&nbsp;</span>mg (blue), 5<span>&nbsp;</span>mg (pink) and 1<span>&nbsp;</span>mg (brown) warfarin tablets (UK colours)</div></div></div>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    

<p>Warfarin consists of a racemic mixture of two active enantiomers—<i>R</i>- and <i>S</i>- forms—each of which is cleared by different pathways. S-warfarin is 2–5 times more potent than the R-isomer in producing an anticoagulant response.<span class="mw-ref" id="cite_ref-Hirsh_2003_14-2"><a href="#cite_note-Hirsh_2003-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Both the enantiomers of warfarin undergo CYP-mediated metabolism by many different CYPs to form 3',4',6,7,8 and 10-hydroxy warfarin metabolites, major being 7-OH warfarin formed from S-warfarin by CYP2C9 and 10-OH warfarin from R-warfarin by CYP3A4.<span class="mw-ref" id="cite_ref-70"><a href="#cite_note-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span></p>

<p>Warfarin is slower-acting than the common anticoagulant <a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">heparin</a>, though it has a number of advantages. Heparin must be given by injection, whereas warfarin is available orally. Warfarin has a long half-life and need only be given once a day. Heparin can also cause a prothrombotic condition, heparin-induced thrombocytopenia (an <a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">antibody</a>-mediated decrease in platelet levels), which increases the risk for thrombosis. It takes several days for warfarin to reach the therapeutic effect since the circulating coagulation factors are not affected by the drug (thrombin has a half-life time of days). Warfarin's long half-life means that it remains effective for several days after it is stopped.  Furthermore, if given initially without additional anticoagulant cover, it can increase thrombosis risk (see below). For these main reasons, hospitalised patients are usually given heparin with warfarin initially, the heparin covering the 3–5-day lag period and being withdrawn after a few days.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<p>While warfarin is one of several drugs popularly referred to as a "blood thinner", this is a misnomer since it does not affect the viscosity of blood.<span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span></p>

<p>Warfarin inhibits the <a href="Vitamin_K.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_K" title="Vitamin K">vitamin K</a>-dependent synthesis of biologically active forms of the clotting factors <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Thrombin" title="Thrombin">II</a>, VII, IX and X, as well as the regulatory factors protein C, protein S, and protein Z.<span class="mw-ref" id="cite_ref-Ansell_49-1"><a href="#cite_note-Ansell-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-72"><a href="#cite_note-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span> Other proteins not involved in blood clotting, such as osteocalcin, or matrix Gla protein, may also be affected.
The precursors of these factors require gamma carboxylation of their <a href="Glutamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glutamic_acid" title="Glutamic acid">glutamic acid</a> residues to allow the coagulation factors to bind to phospholipid surfaces inside blood vessels, on the vascular endothelium. The enzyme that carries out the carboxylation of glutamic acid is gamma-glutamyl carboxylase. The carboxylation reaction will proceed only if the carboxylase enzyme is able to convert a reduced form of vitamin K (vitamin K hydroquinone) to vitamin K epoxide at the same time. The vitamin K epoxide is in turn recycled back to vitamin K and vitamin K <a href="Hydroquinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroquinone" title="Hydroquinone">hydroquinone</a> by another enzyme, the vitamin K epoxide reductase (VKOR). Warfarin inhibits epoxide reductase<span class="mw-ref" id="cite_ref-Whitlon_73-0"><a href="#cite_note-Whitlon-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span> (specifically the VKORC1 subunit<span class="mw-ref" id="cite_ref-74"><a href="#cite_note-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-pmid14765194_75-0"><a href="#cite_note-pmid14765194-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span>), thereby diminishing available vitamin K and vitamin K hydroquinone in the tissues, which inhibits the carboxylation activity of the glutamyl carboxylase. When this occurs, the coagulation factors are no longer carboxylated at certain <a href="Glutamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glutamic_acid" title="Glutamic acid">glutamic acid</a> residues, and are incapable of binding to the endothelial surface of blood vessels, and are thus biologically inactive. As the body's stores of previously produced active factors degrade (over several days) and are replaced by inactive factors, the anticoagulation effect becomes apparent. The coagulation factors are produced, but have decreased functionality due to undercarboxylation; they are collectively referred to as PIVKAs (proteins induced [by] vitamin K absence/antagonism), and individual coagulation factors as PIVKA-<i>number</i> (e.g., PIVKA-II). The end result of warfarin use, therefore, is to diminish blood clotting in the patient.</p>

<p>When warfarin is newly started, it may <i>promote</i> clot formation temporarily. This is because the level of protein C and protein S are also dependent on vitamin K activity. Warfarin causes decline in protein C levels in first 36 hours. In addition, reduced levels of protein S lead to a reduction in activity of protein C (for which it is the co-factor) and therefore reduced degradation of factor Va and <a href="Factor_VIII.htm" tppabs="https://ptable.com/wiki/compounds/A/Factor_VIII" title="Factor VIII">factor VIIIa</a>. Although loading doses of warfarin over 5<span>&nbsp;</span>mg also produce a precipitous decline in factor VII, resulting in an initial prolongation of the INR, full antithrombotic effect does not take place until significant reduction in factor II occurs days later. The haemostasis system becomes temporarily biased towards thrombus formation, leading to a prothrombotic state. Thus, when warfarin is loaded rapidly at greater than 5<span>&nbsp;</span>mg per day, it is beneficial to co-administer <a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">heparin</a>, an anticoagulant that acts upon antithrombin and helps reduce the risk of thrombosis, with warfarin therapy for four to five days, in order to have the benefit of anticoagulation from heparin until the full effect of warfarin has been achieved.<span class="mw-ref" id="cite_ref-76"><a href="#cite_note-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span><span class="mw-ref" id="cite_ref-77"><a href="#cite_note-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacogenomics">Pharmacogenomics</h3></summary>
    
<p>Warfarin activity is determined partially by genetic factors. Polymorphisms in two genes (<i>VKORC1</i> and <i>CYP2C9</i>) play a particularly large role in response to warfarin.</p>

<p>VKORC1 polymorphisms explain 30% of the dose variation between patients:<span class="mw-ref" id="cite_ref-pmid15883587_78-0"><a href="#cite_note-pmid15883587-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span> particular mutations make VKORC1 less susceptible to suppression by warfarin.<span class="mw-ref" id="cite_ref-pmid14765194_75-1"><a href="#cite_note-pmid14765194-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span> There are two main haplotypes that explain 25% of variation: low-dose haplotype group (A) and a high-dose haplotype group (B).<span class="mw-ref" id="cite_ref-pmid15930419_79-0"><a href="#cite_note-pmid15930419-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> <i>VKORC1</i> polymorphisms explain why African Americans are on average relatively resistant to warfarin (higher proportion of group B haplotypes), while Asian Americans are generally more sensitive (higher proportion of group A haplotypes).<span class="mw-ref" id="cite_ref-pmid15930419_79-1"><a href="#cite_note-pmid15930419-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> Group A <i>VKORC1</i> polymorphisms lead to a more rapid achievement of a therapeutic INR, but also a shorter time to reach an INR over 4, which is associated with bleeding.<span class="mw-ref" id="cite_ref-pmid18322281_80-0"><a href="#cite_note-pmid18322281-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></p>

<p><i>CYP2C9</i> polymorphisms explain 10% of the dose variation between patients,<span class="mw-ref" id="cite_ref-pmid15883587_78-1"><a href="#cite_note-pmid15883587-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span> mainly among Caucasian patients as these variants are rare in African American and most Asian populations.<span class="mw-ref" id="cite_ref-pmid15714076_81-0"><a href="#cite_note-pmid15714076-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span> These <i>CYP2C9</i> polymorphisms do not influence time to effective INR as opposed to<i>VKORC1</i>, but does shorten the time to INR &gt;4.<span class="mw-ref" id="cite_ref-pmid18322281_80-1"><a href="#cite_note-pmid18322281-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></p>

<p>Despite the promise of pharmacogenomic testing in warfarin dosing, its use in clinical practice is controversial.  In August 2009 the Centers for Medicare and Medicaid Services concluded that "the available evidence does not demonstrate that pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness improves health outcomes in Medicare beneficiaries."<span class="mw-ref" id="cite_ref-82"><a href="#cite_note-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> A 2014 meta-analysis showed that using genotype-based dosing did not confer benefit in terms of time within therapeutic range, excessive anticoagulation (as defined by INR greater than 4), or a reduction in either major bleeding or thromboembolic events.<span class="mw-ref" id="cite_ref-Stergiopoulos_83-0"><a href="#cite_note-Stergiopoulos-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>In the early 1920s, there was an outbreak of a previously unrecognized cattle disease in the northern United States and Canada. Cattle were haemorrhaging after minor procedures, and on some occasions spontaneously.<span class="mw-ref" id="cite_ref-Distillations_84-0"><a href="#cite_note-Distillations-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span> For example, 21 out of 22 cows died after dehorning, and 12 out of 25 bulls died after castration. All of these animals had bled to death.<span class="mw-ref" id="cite_ref-Laurence_1973_23.4-23.5_85-0"><a href="#cite_note-Laurence_1973_23.4-23.5-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span></p>

<p>In 1921, Frank Schofield, a Canadian veterinary pathologist, determined that the cattle were ingesting moldy silage made from sweet clover, and that this was functioning as a potent anticoagulant.<span class="mw-ref" id="cite_ref-Distillations_84-1"><a href="#cite_note-Distillations-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span> Only spoiled hay made from sweet clover (grown in northern states of the US and in Canada since the turn of the century) produced the disease.<span class="mw-ref" id="cite_ref-86"><a href="#cite_note-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> Schofield separated good clover stalks and damaged clover stalks from the same hay mow, and fed each to a different rabbit. The rabbit that had ingested the good stalks remained well, but the rabbit that had ingested the damaged stalks died from a haemorrhagic illness. A duplicate experiment with a different sample of clover hay produced the same result.<span class="mw-ref" id="cite_ref-Laurence_1973_23.4-23.5_85-1"><a href="#cite_note-Laurence_1973_23.4-23.5-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> In 1929, North Dakota veterinarian Lee M. Roderick demonstrated that the condition was due to a lack of functioning <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prothrombin" title="Prothrombin" class="mw-redirect">prothrombin</a>.<span class="mw-ref" id="cite_ref-87"><a href="#cite_note-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span></p>

<p>The identity of the anticoagulant substance in spoiled sweet clover remained a mystery until 1940. In 1933 Karl Paul Link and his lab of chemists working at the University of Wisconsin set out to isolate and characterize the haemorrhagic agent from the spoiled hay.<span class="mw-ref" id="cite_ref-Distillations_84-2"><a href="#cite_note-Distillations-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span> It took five years before Link's student Harold A. Campbell recovered 6<span>&nbsp;</span>mg of crystalline anticoagulant. Next, Link's student Mark A. Stahmann took over the project and initiated a large-scale extraction, isolating 1.8 g of recrystallized anticoagulant in about 4 months. This was enough material for Stahmann and Charles F. Huebner to check their results against Campbell's, and to thoroughly characterize the compound. Through degradation experiments they established that the anticoagulant was 3,3'-methylenebis-(4-hydroxycoumarin), which they later named <a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">dicoumarol</a>. They confirmed their results by synthesizing dicoumarol and proving in 1940 that it was identical to the naturally occurring agent.<span class="mw-ref" id="cite_ref-88"><a href="#cite_note-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span></p>

<p>Dicoumarol was a product of the plant molecule <a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">coumarin</a> (not to be confused with Couma<b>d</b>in, a later tradename for warfarin). Coumarin is now known to be present in many plants, and produces the notably sweet smell of freshly cut grass or hay and plants like sweet grass; in fact, the plant's high content of coumarin is responsible for the original common name of "sweet clover", which is named for its sweet smell, not its bitter taste.<span class="mw-ref" id="cite_ref-Laurence_1973_23.4-23.5_85-2"><a href="#cite_note-Laurence_1973_23.4-23.5-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> They are present notably in woodruff (<i>Galium odoratum</i>, Rubiaceae), and at lower levels in licorice, lavender, and various other species. However, coumarins themselves do not influence clotting or warfarin-like action, but must first be metabolized by various fungi into compounds such as 4-hydroxycoumarin, then further (in the presence of naturally occurring <a href="Formaldehyde.htm" tppabs="https://ptable.com/wiki/compounds/A/Formaldehyde" title="Formaldehyde">formaldehyde</a>) into <a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">dicoumarol</a>, in order to have any anticoagulant properties. Fungal attack of the damaged and dying clover stalks explained the presence of the anticoagulant only in spoiled clover silages; dicoumarol is considered to be a fermentation product and mycotoxin.<span class="mw-ref" id="cite_ref-Bye_1970_89-0"><a href="#cite_note-Bye_1970-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></p>

<p>Over the next few years, numerous similar chemicals (specifically 4-hydroxycoumarins with a large aromatic substituent at the <b>3</b> position) were found to have the same anticoagulant properties. The first drug in the class to be widely commercialized was <a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">dicoumarol</a> itself, patented in 1941 and later used as a pharmaceutical. Karl Link continued working on developing more potent coumarin-based anticoagulants for use as rodent poisons, resulting in warfarin in 1948. The name "warfarin" stems from the acronym <i>WARF</i>, for <i>Wisconsin Alumni Research Foundation</i> + the ending <i>-arin</i> indicating its link with coumarin. Warfarin was first registered for use as a rodenticide in the US in 1948, and was immediately popular. Although warfarin was developed by Link, the Wisconsin Alumni Research Foundation financially supported the research and was assigned the patent.<span class="mw-ref" id="cite_ref-pmid13619027_90-0"><a href="#cite_note-pmid13619027-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span></p>

<p>After an incident in 1951, in which an army inductee attempted suicide with multiple doses of warfarin in rodenticide but recovered fully after presenting to a Naval Hospital and being treated with vitamin K (by then known as a specific antidote),<span class="mw-ref" id="cite_ref-pmid13619027_90-1"><a href="#cite_note-pmid13619027-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> studies began in the use of warfarin as a therapeutic anticoagulant.<span class="mw-ref" id="cite_ref-Distillations_84-3"><a href="#cite_note-Distillations-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span> It was found to be generally superior to dicoumarol, and in 1954 was approved for medical use in humans. An early recipient of warfarin was US President Dwight Eisenhower, who was prescribed the drug after having a heart attack in 1955.<span class="mw-ref" id="cite_ref-pmid13619027_90-2"><a href="#cite_note-pmid13619027-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span></p>

<p>The exact mechanism of action remained unknown until it was demonstrated, in 1978, that warfarin inhibits the enzyme epoxide reductase, and hence interferes with vitamin K metabolism.<span class="mw-ref" id="cite_ref-Whitlon_73-1"><a href="#cite_note-Whitlon-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span></p>

<p>It has been posited that Lavrenty Beria, Nikita Khrushchev, and others conspired to use warfarin to poison Soviet leader Joseph Stalin. Warfarin is tasteless and colourless, and produces symptoms similar to those that Stalin exhibited.<span class="mw-ref" id="cite_ref-91"><a href="#cite_note-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pest_control">Pest control</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Rodents">Rodents</h3></summary>
    
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="4-Hydroxycoumarins.htm" tppabs="https://ptable.com/wiki/compounds/A/4-hydroxycoumarins" title="4-hydroxycoumarins" class="mw-redirect">4-hydroxycoumarins</a></div>
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Rattenvergifwaarschuwing_edit.JPG" tppabs="https://ptable.com/wiki/compounds/I/m/Rattenvergifwaarschuwing_edit.JPG" data-file-width="2560" data-file-height="1920" data-file-type="bitmap" height="165" width="220"><div class="thumbcaption" style="text-align: left">Warning label on a tube of rat poison laid on a dike of the Scheldt river in <span class="new">Steendorp, Belgium</span>. The tube contains <a href="Bromadiolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromadiolone" title="Bromadiolone">bromadiolone</a>, a second-generation ("super-warfarin") anticoagulant.</div></div></div>
<p>Coumarins (4-hydroxycoumarin derivatives) are used as rodenticides for controlling rats and mice in residential, industrial, and agricultural areas. Warfarin is both odorless and tasteless, and is effective when mixed with food bait, because the rodents will return to the bait and continue to feed over a period of days until a lethal dose is accumulated (considered to be 1<span>&nbsp;</span>mg/kg/day over about six days). It may also be mixed with <a href="Talc.htm" tppabs="https://ptable.com/wiki/compounds/A/Talc" title="Talc">talc</a> and used as a <i>tracking powder</i>, which accumulates on the animal's skin and fur, and is subsequently consumed during grooming. The LD<sub style="font-size:-1">50</sub> is 50–500<span>&nbsp;</span>mg/kg. The IDLH value is 100<span>&nbsp;</span>mg/m<sup>3</sup> (warfarin; various species).<span class="mw-ref" id="cite_ref-92"><a href="#cite_note-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span></p>

<p>The use of warfarin itself as a rat poison is now declining, because many rat populations have developed resistance to it, and poisons of considerably greater potency are now available. Other 4-hydroxycoumarins used as rodenticides include <a href="Coumatetralyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumatetralyl" title="Coumatetralyl">coumatetralyl</a> and <a href="Brodifacoum.htm" tppabs="https://ptable.com/wiki/compounds/A/Brodifacoum" title="Brodifacoum">brodifacoum</a>, which is sometimes referred to as "super-warfarin", because it is more potent, longer-acting, and effective even in rat and mouse populations that are resistant to warfarin. Unlike warfarin, which is readily excreted, newer anticoagulant poisons also accumulate in the liver and kidneys after ingestion.<span class="mw-ref" id="cite_ref-NZToxins_93-0"><a href="#cite_note-NZToxins-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span> However, such rodenticides may also accumulate in birds of prey and other animals that eat the poisoned rodents or baits.<span class="mw-ref" id="cite_ref-94"><a href="#cite_note-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Vampire_bats">Vampire bats</h3></summary>
    
<p>Warfarin is used to cull vampire bat populations in areas where human–wildlife conflict is a concern.<span class="mw-ref" id="cite_ref-Johnson_2014_95-0"><a href="#cite_note-Johnson_2014-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span> Vampire bats are captured with mist nets and coated with a combination of <a href="Petroleum_jelly.htm" tppabs="https://ptable.com/wiki/compounds/A/Petroleum_jelly" title="Petroleum jelly">petroleum jelly</a> and warfarin. The bat returns to its roost and other members of the roost become poisoned as well by ingesting the warfarin after reciprocal grooming.<span class="mw-ref" id="cite_ref-Johnson_2014_95-1"><a href="#cite_note-Johnson_2014-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span> Suspected vampire bat roosts may also be coated in the warfarin solution, though this kills other bat species and remains in the environment for years.<span class="mw-ref" id="cite_ref-Johnson_2014_95-2"><a href="#cite_note-Johnson_2014-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span> The efficacy of killing vampire bats to reduce rabies transmission is questionable, however; a study in Peru showed that culling programs did not lead to lower transmission rates of rabies to livestock and humans.<span class="mw-ref" id="cite_ref-Streicker_2012_96-0"><a href="#cite_note-Streicker_2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Occupational_safety">Occupational safety</h2></summary>
    
<p>People can be exposed to warfarin in the workplace by breathing it in, swallowing it, skin absorption, and eye contact. The Occupational Safety and Health Administration (OSHA) has set the legal limit (permissible exposure limit) for warfarin exposure in the workplace as 0.1<span>&nbsp;</span>mg/m<sup>3</sup> over an 8-hour workday. The National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) of 0.1<span>&nbsp;</span>mg/m<sup>3</sup> over an 8-hour workday. At levels of 100<span>&nbsp;</span>mg/m<sup>3</sup>, warfarin is immediately dangerous to life and health.<span class="mw-ref" id="cite_ref-97"><a href="#cite_note-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span></p>

<p>It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.<span class="mw-ref" id="cite_ref-gov-right-know_98-0"><a href="#cite_note-gov-right-know-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Names">Names</h2></summary>
    
<p>Warfarin is a derivative of <a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">dicoumarol</a>, an anticoagulant originally discovered in spoiled sweet clover. Dicoumarol, in turn, is from <a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">coumarin</a>, a sweet-smelling but coagulation-inactive chemical found in "sweet" clover and tonka beans (also known as <i>cumaru</i> from which coumarin's name derives). The name <i>warfarin</i> stems from its discovery at the University of Wisconsin, incorporating the acronym for the organization that funded the key research, <i>WARF</i> for the Wisconsin Alumni Research Foundation and the ending <i>-arin</i>, indicating its link with coumarin.</p>

<p>The drug is marketed under many brand and generic names including Aldocumar, Anasmol, Anticoag, Befarin, Cavamed, Cicoxil, Circuvit, Cofarin, Coumadin, Coumadine, Cumar, Farin, Foley, Haemofarin, Jantoven, Kovar, Lawarin, Maforan, Marevan, Marfarin, Marivanil, Martefarin, Morfarin, Orfarin, Panwarfin, Scheme, Simarc, Varfarin, Varfarins, Varfine, Waran, Warcok, Warf, Warfareks, Warfarin, Warfarina, Warfarine, Warfarinum, Warfen, Warfin, Warik, Warin, Warlin, and Zyfarin.<span class="mw-ref" id="cite_ref-brands_1-2"><a href="#cite_note-brands-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>
<div style="clear:both;"></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-brands-1"> <span id="mw-reference-text-cite_note-brands-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/warfarin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/warfarin.html'" tppabs="https://www.drugs.com/international/warfarin.html" class="external text external">"Warfarin international brands"</a>. Drugs.com. <a href="javascript:if(confirm('https://web.archive.org/web/20170405172058/https://www.drugs.com/international/warfarin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170405172058/https://www.drugs.com/international/warfarin.html'" tppabs="https://web.archive.org/web/20170405172058/https://www.drugs.com/international/warfarin.html" class="external text external">Archived</a> from the original on 5 April 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">4 April</span> 2017</span>.</cite></span></li><li id="cite_note-Drugs.com_pregnancy-2"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/warfarin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/warfarin.html'" tppabs="https://www.drugs.com/pregnancy/warfarin.html" class="external text external">"Warfarin Use During Pregnancy"</a>. <i>Drugs.com</i>. 4 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">7 February</span> 2020</span>.</cite></span></li><li id="cite_note-PCK-3"> <span id="mw-reference-text-cite_note-PCK-3" class="mw-reference-text"><cite id="CITEREFHolford1986" class="citation journal cs1">Holford NH (December 1986). "Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship". <i>Clinical Pharmacokinetics</i>. <b>11</b> (6): 483–504. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-198611060-00005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-198611060-00005'" tppabs="https://doi.org/10.2165%2F00003088-198611060-00005" class="external text external">10.2165/00003088-198611060-00005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3542339  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3542339'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3542339" class="external text external">3542339</a>.</cite></span></li><li id="cite_note-TGA-4"> <span id="mw-reference-text-cite_note-TGA-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3'" tppabs="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3" class="external text external">"PRODUCT INFORMATION COUMADIN"</a> <span class="cs1-format">(PDF)</span>. <i>TGA eBusiness Services</i>. Aspen Pharma Pty Ltd. 19 January 2010. <a href="javascript:if(confirm('https://web.archive.org/web/20151017135417/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151017135417/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3'" tppabs="https://web.archive.org/web/20151017135417/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3" class="external text external">Archived</a> from the original on 17 October 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">11 December</span> 2013</span>.</cite></span></li><li id="cite_note-AHFS2017-5"> <span id="mw-reference-text-cite_note-AHFS2017-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/warfarin-sodium.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/warfarin-sodium.html'" tppabs="https://www.drugs.com/monograph/warfarin-sodium.html" class="external text external">"Warfarin Sodium"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20180612143838/https://www.drugs.com/monograph/warfarin-sodium.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20180612143838/https://www.drugs.com/monograph/warfarin-sodium.html'" tppabs="https://web.archive.org/web/20180612143838/https://www.drugs.com/monograph/warfarin-sodium.html" class="external text external">Archived</a> from the original on 12 June 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2017</span>.</cite></span></li><li id="cite_note-Ag2012-6"> <span id="mw-reference-text-cite_note-Ag2012-6" class="mw-reference-text"><cite id="CITEREFAgenoGallusWittkowskyCrowther2012" class="citation journal cs1">Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (February 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278051'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278051" class="external text external">"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</a>. <i>Chest</i>. <b>141</b> (2 Suppl): e44S–e88S. doi:<a href="javascript:if(confirm('https://doi.org/10.1378%2Fchest.11-2292  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1378%2Fchest.11-2292'" tppabs="https://doi.org/10.1378%2Fchest.11-2292" class="external text external">10.1378/chest.11-2292</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278051'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278051" class="external text external">3278051</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22315269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22315269'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22315269" class="external text external">22315269</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFArcangeloPeterson2006" class="citation book cs1">Arcangelo VP, Peterson AM (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774'" tppabs="https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774" class="external text external"><i>Pharmacotherapeutics for Advanced Practice: A Practical Approach</i></a>. Lippincott Williams &amp; Wilkins. p.<span>&nbsp;</span>774. ISBN<span>&nbsp;</span><bdi>978-0-7817-5784-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170918185711/https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170918185711/https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774'" tppabs="https://web.archive.org/web/20170918185711/https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774" class="external text external">Archived</a> from the original on 18 September 2017.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite id="CITEREFRavina2011" class="citation book cs1">Ravina E (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148'" tppabs="https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148" class="external text external"><i>The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs</i></a>. John Wiley &amp; Sons. p.<span>&nbsp;</span>148. ISBN<span>&nbsp;</span><bdi>978-3-527-32669-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170918185711/https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170918185711/https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148'" tppabs="https://web.archive.org/web/20170918185711/https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148" class="external text external">Archived</a> from the original on 18 September 2017.</cite></span></li><li id="cite_note-WHO21st-9"> <span id="mw-reference-text-cite_note-WHO21st-9" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-BNF69-10"> <span id="mw-reference-text-cite_note-BNF69-10" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary</i>. <i>BNF 69</i> (69 ed.). British Medical Association. 2015. pp.<span>&nbsp;</span>154–155. ISBN<span>&nbsp;</span><bdi>978-0-85711-156-2</bdi>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/Warfarin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/Warfarin'" tppabs="https://clincalc.com/DrugStats/Drugs/Warfarin" class="external text external">"Warfarin - Drug Usage Statistics"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-AHFS-13"> <span id="mw-reference-text-cite_note-AHFS-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/coumadin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/coumadin.html'" tppabs="https://www.drugs.com/monograph/coumadin.html" class="external text external">"Coumadin"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20110203081242/http://www.drugs.com/monograph/coumadin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110203081242/http://www.drugs.com/monograph/coumadin.html'" tppabs="https://web.archive.org/web/20110203081242/http://www.drugs.com/monograph/coumadin.html" class="external text external">Archived</a> from the original on 3 February 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">3 April</span> 2011</span>.</cite></span></li><li id="cite_note-Hirsh_2003-14"> <span id="mw-reference-text-cite_note-Hirsh_2003-14" class="mw-reference-text"><cite id="CITEREFHirshFusterAnsellHalperin2003" class="citation journal cs1">Hirsh J, Fuster V, Ansell J, Halperin JL (May 2003). "American Heart Association/American College of Cardiology Foundation guide to warfarin therapy". <i>Journal of the American College of Cardiology</i>. <b>41</b> (9): 1633–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0735-1097%2803%2900416-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0735-1097%2803%2900416-9'" tppabs="https://doi.org/10.1016%2FS0735-1097%2803%2900416-9" class="external text external">10.1016/S0735-1097(03)00416-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12742309  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12742309'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12742309" class="external text external">12742309</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFKimKimKimUhm2018" class="citation journal cs1">Kim, In-Soo; Kim, Hyun-Jung; Kim, Tae-Hoon; Uhm, Jae-Sun; Joung, Boyoung; Lee, Moon-Hyoung; Pak, Hui-Nam (2018). <a href="javascript:if(confirm('https://doi.org/10.1016/j.jjcc.2018.03.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.jjcc.2018.03.009'" tppabs="https://doi.org/10.1016/j.jjcc.2018.03.009" class="external text external">"Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis"</a>. <i>Journal of Cardiology</i>. <b>72</b> (4): 284–291. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jjcc.2018.03.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jjcc.2018.03.009'" tppabs="https://doi.org/10.1016%2Fj.jjcc.2018.03.009" class="external text external">10.1016/j.jjcc.2018.03.009</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29706404  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29706404'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29706404" class="external text external">29706404</a>.</cite></span></li><li id="cite_note-Holbrook2005-16"> <span id="mw-reference-text-cite_note-Holbrook2005-16" class="mw-reference-text"><cite id="CITEREFHolbrookPereiraLabirisMcDonald2005" class="citation journal cs1">Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (May 2005). <a href="javascript:if(confirm('https://doi.org/10.1001/archinte.165.10.1095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/archinte.165.10.1095'" tppabs="https://doi.org/10.1001/archinte.165.10.1095" class="external text external">"Systematic overview of warfarin and its drug and food interactions"</a>. <i>Archives of Internal Medicine</i>. <b>165</b> (10): 1095–106. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Farchinte.165.10.1095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchinte.165.10.1095'" tppabs="https://doi.org/10.1001%2Farchinte.165.10.1095" class="external text external">10.1001/archinte.165.10.1095</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15911722  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15911722'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15911722" class="external text external">15911722</a>.</cite></span></li><li id="cite_note-Perry_2010-17"> <span id="mw-reference-text-cite_note-Perry_2010-17" class="mw-reference-text"><cite id="CITEREFPerryFitzmauriceKitchenMackie2010" class="citation journal cs1">Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S (September 2010). "Point-of-care testing in haemostasis". <i>British Journal of Haematology</i>. <b>150</b> (5): 501–14. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2141.2010.08223.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2141.2010.08223.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2141.2010.08223.x" class="external text external">10.1111/j.1365-2141.2010.08223.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20618331  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20618331'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20618331" class="external text external">20618331</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFBaglinKeelingWatson2006" class="citation journal cs1">Baglin TP, Keeling DM, Watson HG (February 2006). "Guidelines on oral anticoagulation (warfarin): third edition—2005 update". <i>British Journal of Haematology</i>. <b>132</b> (3): 277–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2141.2005.05856.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2141.2005.05856.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2141.2005.05856.x" class="external text external">10.1111/j.1365-2141.2005.05856.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16409292  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16409292'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16409292" class="external text external">16409292</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite id="CITEREFNational_Institutes_of_Health" class="citation web cs1">National Institutes of Health. <a href="javascript:if(confirm('https://web.archive.org/web/20131020203725/http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131020203725/http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf'" tppabs="https://web.archive.org/web/20131020203725/http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf" class="external text external">"important information to know when you are taking<span>&nbsp;</span>: Coumadine and vitamine K"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf'" tppabs="http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 20 October 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">27 March</span> 2014</span>.</cite></span></li><li id="cite_note-Holbrook2012-20"> <span id="mw-reference-text-cite_note-Holbrook2012-20" class="mw-reference-text"><cite id="CITEREFHolbrookSchulmanWittVandvik2012" class="citation journal cs1">Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH (February 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278055'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278055" class="external text external">"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</a>. <i>Chest</i>. <b>141</b> (2 Suppl): e152S–e184S. doi:<a href="javascript:if(confirm('https://doi.org/10.1378%2Fchest.11-2295  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1378%2Fchest.11-2295'" tppabs="https://doi.org/10.1378%2Fchest.11-2295" class="external text external">10.1378/chest.11-2295</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278055'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278055" class="external text external">3278055</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22315259  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22315259'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22315259" class="external text external">22315259</a>.</cite></span></li><li id="cite_note-pmid15926414-21"> <span id="mw-reference-text-cite_note-pmid15926414-21" class="mw-reference-text"><cite id="CITEREFEbell2005" class="citation journal cs1">Ebell MH (May 2005). <a href="javascript:if(confirm('https://www.aafp.org/afp/2005/0515/p1979.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.aafp.org/afp/2005/0515/p1979.html'" tppabs="https://www.aafp.org/afp/2005/0515/p1979.html" class="external text external">"Evidence-based adjustment of warfarin (Coumadin) doses"</a>. <i>American Family Physician</i>. <b>71</b> (10): 1979–82. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15926414  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15926414'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15926414" class="external text external">15926414</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20180201075216/https://www.aafp.org/afp/2005/0515/p1979.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20180201075216/https://www.aafp.org/afp/2005/0515/p1979.html'" tppabs="https://web.archive.org/web/20180201075216/https://www.aafp.org/afp/2005/0515/p1979.html" class="external text external">Archived</a> from the original on 1 February 2018.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.mayoclinic.com/health/warfarin/AN00455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mayoclinic.com/health/warfarin/AN00455'" tppabs="http://www.mayoclinic.com/health/warfarin/AN00455" class="external text external">"Warfarin diet: What foods should I avoid?"</a>. Mayoclinic.com. <a href="javascript:if(confirm('https://web.archive.org/web/20110824075323/http://www.mayoclinic.com/health/warfarin/AN00455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110824075323/http://www.mayoclinic.com/health/warfarin/AN00455'" tppabs="https://web.archive.org/web/20110824075323/http://www.mayoclinic.com/health/warfarin/AN00455" class="external text external">Archived</a> from the original on 24 August 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">9 August</span> 2011</span>.</cite></span></li><li id="cite_note-Ansell2005-23"> <span id="mw-reference-text-cite_note-Ansell2005-23" class="mw-reference-text"><cite id="CITEREFAnsellJacobsonLevyVöller2005" class="citation journal cs1">Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM (March 2005). <a href="javascript:if(confirm('https://web.archive.org/web/20160303221536/http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160303221536/http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf'" tppabs="https://web.archive.org/web/20160303221536/http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf" class="external text external">"Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation"</a> <span class="cs1-format">(PDF)</span>. <i>International Journal of Cardiology</i>. <b>99</b> (1): 37–45. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijcard.2003.11.008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijcard.2003.11.008'" tppabs="https://doi.org/10.1016%2Fj.ijcard.2003.11.008" class="external text external">10.1016/j.ijcard.2003.11.008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15721497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15721497'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15721497" class="external text external">15721497</a>. Archived from <a href="javascript:if(confirm('http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf'" tppabs="http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 3 March 2016.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFHeneghanAlonso-CoelloGarcia-AlaminoPerera2006" class="citation journal cs1">Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P (February 2006). <a href="javascript:if(confirm('https://web.archive.org/web/20120319160502/http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120319160502/http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf'" tppabs="https://web.archive.org/web/20120319160502/http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf" class="external text external">"Self-monitoring of oral anticoagulation: a systematic review and meta-analysis"</a> <span class="cs1-format">(PDF)</span>. <i>Lancet</i>. <b>367</b> (9508): 404–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2806%2968139-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2806%2968139-7'" tppabs="https://doi.org/10.1016%2FS0140-6736%2806%2968139-7" class="external text external">10.1016/S0140-6736(06)68139-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16458764  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16458764'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16458764" class="external text external">16458764</a>. Archived from <a href="javascript:if(confirm('http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf'" tppabs="http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 19 March 2012.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFCukerBurnettTrillerCrowther2019" class="citation journal cs1">Cuker, Adam; Burnett, Allison; Triller, Darren; Crowther, Mark; Ansell, Jack; Van Cott, Elizabeth M.; Wirth, Diane; Kaatz, Scott (June 2019). <a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30916798/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30916798/'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30916798/" class="external text external">"Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum"</a>. <i>American Journal of Hematology</i>. <b>94</b> (6): 697–709. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fajh.25475  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fajh.25475'" tppabs="https://doi.org/10.1002%2Fajh.25475" class="external text external">10.1002/ajh.25475</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1096-8652  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1096-8652'" tppabs="https://www.worldcat.org/issn/1096-8652" class="external text external">1096-8652</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30916798  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30916798'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30916798" class="external text external">30916798</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFLevyAgenoChanCrowther2016" class="citation journal cs1">Levy, J. H.; Ageno, W.; Chan, N. C.; Crowther, M.; Verhamme, P.; Weitz, J. I. (2016). <a href="javascript:if(confirm('https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.13227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.13227'" tppabs="https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.13227" class="external text external">"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH"</a>. <i>Journal of Thrombosis and Haemostasis</i>. <b>14</b> (3): 623–627. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fjth.13227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fjth.13227'" tppabs="https://doi.org/10.1111%2Fjth.13227" class="external text external">10.1111/jth.13227</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1538-7836  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1538-7836'" tppabs="https://www.worldcat.org/issn/1538-7836" class="external text external">1538-7836</a>.</cite></span></li><li id="cite_note-martindale-27"> <span id="mw-reference-text-cite_note-martindale-27" class="mw-reference-text">Brayfield A (ed), Martindale: The Complete Drug Reference [online] London: Pharmaceutical Press [accessed on 24 April 2017]</span></li><li id="cite_note-FDA2015-28"> <span id="mw-reference-text-cite_note-FDA2015-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf" class="external text external">"Coumadin"</a> <span class="cs1-format">(PDF)</span>. <i>fda.gov</i>. October 2015. <a href="javascript:if(confirm('https://web.archive.org/web/20170623024610/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170623024610/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf'" tppabs="https://web.archive.org/web/20170623024610/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 23 June 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">24 April</span> 2017</span>.</cite></span></li><li id="cite_note-rapini-29"> <span id="mw-reference-text-cite_note-rapini-29" class="mw-reference-text"><cite id="CITEREFBologniaJorizzoRapini2008" class="citation book cs1">Bolognia JL, Jorizzo JL, Rapini RP (2008). <span class="cs1-lock-limited"><a href="javascript:if(confirm('https://archive.org/details/dermatologyvolum00mdje  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/dermatologyvolum00mdje'" tppabs="https://archive.org/details/dermatologyvolum00mdje" class="external text external"><i>Dermatology</i></a></span> (2nd ed.). St. Louis, Mo.: Mosby/Elsevier. pp.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/dermatologyvolum00mdje/page/n350  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/dermatologyvolum00mdje/page/n350'" tppabs="https://archive.org/details/dermatologyvolum00mdje/page/n350" class="external text external">331</a>, 340. ISBN<span>&nbsp;</span><bdi>978-1-4160-2999-1</bdi>.</cite></span></li><li id="cite_note-HDT-30"> <span id="mw-reference-text-cite_note-HDT-30" class="mw-reference-text"><cite id="CITEREFMacinaSchardein2007" class="citation book cs1">Macina OT, Schardein JL (2007). <a href="javascript:if(confirm('https://books.google.com/?id=8_Lc58cGZj0C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/?id=8_Lc58cGZj0C'" tppabs="https://books.google.com/?id=8_Lc58cGZj0C" class="external text external">"Warfarin"</a>. <i>Human Developmental Toxicants</i>. Boca Raton: CRC Taylor &amp; Francis. pp.<span>&nbsp;</span>193–4. ISBN<span>&nbsp;</span><bdi>978-0-8493-7229-2</bdi>.</cite> Retrieved on 15 December 2008 through Google Book Search.</span></li><li id="cite_note-Loftus-31"> <span id="mw-reference-text-cite_note-Loftus-31" class="mw-reference-text"><cite id="CITEREFLoftus1995" class="citation book cs1">Loftus CM (1995). <a href="javascript:if(confirm('https://books.google.com/?id=X58R5BqtHmEC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/?id=X58R5BqtHmEC'" tppabs="https://books.google.com/?id=X58R5BqtHmEC" class="external text external">"Fetal toxicity of common neurosurgical drugs"</a>. <i>Neurosurgical Aspects of Pregnancy</i>. Park Ridge, Ill: American Association of Neurological Surgeons. pp.<span>&nbsp;</span>11–3. ISBN<span>&nbsp;</span><bdi>978-1-879284-36-4</bdi>.</cite></span></li><li id="cite_note-Bates_2012-32"> <span id="mw-reference-text-cite_note-Bates_2012-32" class="mw-reference-text"><cite id="CITEREFBatesGreerMiddeldorpVeenstra2012" class="citation journal cs1">Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (February 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054" class="external text external">"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</a>. <i>Chest</i>. <b>141</b> (2 Suppl): e691S–e736S. doi:<a href="javascript:if(confirm('https://doi.org/10.1378%2Fchest.11-2300  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1378%2Fchest.11-2300'" tppabs="https://doi.org/10.1378%2Fchest.11-2300" class="external text external">10.1378/chest.11-2300</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054" class="external text external">3278054</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22315276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22315276'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22315276" class="external text external">22315276</a>.</cite></span></li><li id="cite_note-Garcia2010-33"> <span id="mw-reference-text-cite_note-Garcia2010-33" class="mw-reference-text"><cite id="CITEREFGarciaCrowtherAgeno2010" class="citation journal cs1">Garcia D, Crowther MA, Ageno W (April 2010). "Practical management of coagulopathy associated with warfarin". <i>BMJ</i>. <b>340</b>: c1813. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.c1813  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.c1813'" tppabs="https://doi.org/10.1136%2Fbmj.c1813" class="external text external">10.1136/bmj.c1813</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20404060  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20404060'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20404060" class="external text external">20404060</a>.</cite></span></li><li id="cite_note-Brown2015-34"> <span id="mw-reference-text-cite_note-Brown2015-34" class="mw-reference-text"><cite id="CITEREFBrownWilkersonLove2015" class="citation journal cs1">Brown DG, Wilkerson EC, Love WE (March 2015). "A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons". <i>Journal of the American Academy of Dermatology</i>. <b>72</b> (3): 524–34. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2014.10.027  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2014.10.027'" tppabs="https://doi.org/10.1016%2Fj.jaad.2014.10.027" class="external text external">10.1016/j.jaad.2014.10.027</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25486915  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25486915'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25486915" class="external text external">25486915</a>.</cite></span></li><li id="cite_note-Camm2012-35"> <span id="mw-reference-text-cite_note-Camm2012-35" class="mw-reference-text"><cite id="CITEREFCammLipDe_CaterinaSavelieva2012" class="citation journal cs1">Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG) (November 2012). <a href="javascript:if(confirm('https://doi.org/10.1093/eurheartj/ehs253  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/eurheartj/ehs253'" tppabs="https://doi.org/10.1093/eurheartj/ehs253" class="external text external">"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association"</a>. <i>European Heart Journal</i>. <b>33</b> (21): 2719–47. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Feurheartj%2Fehs253  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Feurheartj%2Fehs253'" tppabs="https://doi.org/10.1093%2Feurheartj%2Fehs253" class="external text external">10.1093/eurheartj/ehs253</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22922413  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22922413'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22922413" class="external text external">22922413</a>.</cite></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite id="CITEREFShoebFang2013" class="citation journal cs1">Shoeb M, Fang MC (April 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888359  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888359'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888359" class="external text external">"Assessing bleeding risk in patients taking anticoagulants"</a>. <i>Journal of Thrombosis and Thrombolysis</i>. <b>35</b> (3): 312–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11239-013-0899-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11239-013-0899-7'" tppabs="https://doi.org/10.1007%2Fs11239-013-0899-7" class="external text external">10.1007/s11239-013-0899-7</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888359  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888359'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888359" class="external text external">3888359</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23479259  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23479259'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23479259" class="external text external">23479259</a>.</cite></span></li><li id="cite_note-pmid17720522-37"> <span id="mw-reference-text-cite_note-pmid17720522-37" class="mw-reference-text"><cite id="CITEREFElliottZimmermanHolden2007" class="citation journal cs1">Elliott MJ, Zimmerman D, Holden RM (September 2007). "Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates". <i>American Journal of Kidney Diseases</i>. <b>50</b> (3): 433–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1053%2Fj.ajkd.2007.06.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1053%2Fj.ajkd.2007.06.017'" tppabs="https://doi.org/10.1053%2Fj.ajkd.2007.06.017" class="external text external">10.1053/j.ajkd.2007.06.017</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17720522  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17720522'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17720522" class="external text external">17720522</a>.</cite></span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><cite id="CITEREFFangGoChangBorowsky2011" class="citation journal cs1">Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE (July 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175766  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175766'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175766" class="external text external">"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study"</a>. <i>Journal of the American College of Cardiology</i>. <b>58</b> (4): 395–401. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2011.03.031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2011.03.031'" tppabs="https://doi.org/10.1016%2Fj.jacc.2011.03.031" class="external text external">10.1016/j.jacc.2011.03.031</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175766  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175766'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175766" class="external text external">3175766</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21757117  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21757117'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21757117" class="external text external">21757117</a>.</cite></span></li><li id="cite_note-pmid17698822-39"> <span id="mw-reference-text-cite_note-pmid17698822-39" class="mw-reference-text"><cite id="CITEREFDelaneyOpatrnyBrophySuissa2007" class="citation journal cs1">Delaney JA, Opatrny L, Brophy JM, Suissa S (August 2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942107  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942107'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942107" class="external text external">"Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding"</a>. <i>CMAJ</i>. <b>177</b> (4): 347–51. doi:<a href="javascript:if(confirm('https://doi.org/10.1503%2Fcmaj.070186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1503%2Fcmaj.070186'" tppabs="https://doi.org/10.1503%2Fcmaj.070186" class="external text external">10.1503/cmaj.070186</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942107  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942107'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942107" class="external text external">1942107</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17698822  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17698822'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17698822" class="external text external">17698822</a>.</cite></span></li><li id="cite_note-pmid10718793-40"> <span id="mw-reference-text-cite_note-pmid10718793-40" class="mw-reference-text"><cite id="CITEREFChanValentiMansfieldStansby2000" class="citation journal cs1">Chan YC, Valenti D, Mansfield AO, Stansby G (March 2000). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928566  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928566'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928566" class="external text external">"Warfarin induced skin necrosis"</a>. <i>The British Journal of Surgery</i>. <b>87</b> (3): 266–72. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2168.2000.01352.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2168.2000.01352.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2168.2000.01352.x" class="external text external">10.1046/j.1365-2168.2000.01352.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928566  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928566'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928566" class="external text external">4928566</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10718793  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10718793'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10718793" class="external text external">10718793</a>.</cite></span></li><li id="cite_note-pmid10448778-41"> <span id="mw-reference-text-cite_note-pmid10448778-41" class="mw-reference-text"><cite id="CITEREFCaraballoHeitAtkinsonSilverstein1999" class="citation journal cs1">Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O'Fallon WM, Castro MR, Melton LJ (1999). <a href="javascript:if(confirm('https://doi.org/10.1001/archinte.159.15.1750  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/archinte.159.15.1750'" tppabs="https://doi.org/10.1001/archinte.159.15.1750" class="external text external">"Long-term use of oral anticoagulants and the risk of fracture"</a>. <i>Archives of Internal Medicine</i>. <b>159</b> (15): 1750–6. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Farchinte.159.15.1750  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchinte.159.15.1750'" tppabs="https://doi.org/10.1001%2Farchinte.159.15.1750" class="external text external">10.1001/archinte.159.15.1750</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10448778  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10448778'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10448778" class="external text external">10448778</a>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite id="CITEREFPilonCastillouxDoraisLeLorier2004" class="citation journal cs1">Pilon D, Castilloux AM, Dorais M, LeLorier J (May 2004). "Oral anticoagulants and the risk of osteoporotic fractures among elderly". <i>Pharmacoepidemiology and Drug Safety</i>. <b>13</b> (5): 289–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fpds.888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fpds.888'" tppabs="https://doi.org/10.1002%2Fpds.888" class="external text external">10.1002/pds.888</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15133779  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15133779'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15133779" class="external text external">15133779</a>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFGageBirman-DeychRadfordNilasena2006" class="citation journal cs1">Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (January 2006). <a href="javascript:if(confirm('https://doi.org/10.1001/archinte.166.2.241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/archinte.166.2.241'" tppabs="https://doi.org/10.1001/archinte.166.2.241" class="external text external">"Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2"</a>. <i>Archives of Internal Medicine</i>. <b>166</b> (2): 241–6. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Farchinte.166.2.241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchinte.166.2.241'" tppabs="https://doi.org/10.1001%2Farchinte.166.2.241" class="external text external">10.1001/archinte.166.2.241</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16432096  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16432096'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16432096" class="external text external">16432096</a>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite id="CITEREFO'KeeffeWoodsBreslinTsapatsaris1992" class="citation journal cs1">O'Keeffe, ST; Woods, BO; Breslin, DJ; Tsapatsaris, NP (November 1992). "Blue toe syndrome. Causes and management". <i>Archives of Internal Medicine</i>. <b>152</b> (11): 2197–202. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Farchinte.1992.00400230023004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchinte.1992.00400230023004'" tppabs="https://doi.org/10.1001%2Farchinte.1992.00400230023004" class="external text external">10.1001/archinte.1992.00400230023004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1444678  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1444678'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1444678" class="external text external">1444678</a>.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite id="CITEREFTalmadgeSpyropoulos2003" class="citation journal cs1">Talmadge DB, Spyropoulos AC (May 2003). "Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". <i>Pharmacotherapy</i>. <b>23</b> (5): 674–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1592%2Fphco.23.5.674.32200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1592%2Fphco.23.5.674.32200'" tppabs="https://doi.org/10.1592%2Fphco.23.5.674.32200" class="external text external">10.1592/phco.23.5.674.32200</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12741443  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12741443'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12741443" class="external text external">12741443</a>.</cite></span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text"><cite id="CITEREFPalaniswamySekhriAronowKalra2011" class="citation journal cs1">Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ (February 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652734  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652734'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652734" class="external text external">"Association of warfarin use with valvular and vascular calcification: a review"</a>. <i>Clinical Cardiology</i>. <b>34</b> (2): 74–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fclc.20865  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fclc.20865'" tppabs="https://doi.org/10.1002%2Fclc.20865" class="external text external">10.1002/clc.20865</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652734  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652734'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652734" class="external text external">6652734</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21298649  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21298649'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21298649" class="external text external">21298649</a>.</cite></span></li><li id="cite_note-Chai2016-47"> <span id="mw-reference-text-cite_note-Chai2016-47" class="mw-reference-text"><cite id="CITEREFChai-AdisaksophaHillisSiegalMovilla2016" class="citation journal cs1">Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, Crowther M (October 2016). "Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis". <i>Thrombosis and Haemostasis</i>. <b>116</b> (5): 879–890. doi:<a href="javascript:if(confirm('https://doi.org/10.1160%2FTH16-04-0266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1160%2FTH16-04-0266'" tppabs="https://doi.org/10.1160%2FTH16-04-0266" class="external text external">10.1160/TH16-04-0266</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27488143  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27488143'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27488143" class="external text external">27488143</a>.</cite></span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text"><cite id="CITEREFTornkvistSmithLabaf2018" class="citation journal cs1">Tornkvist, M; Smith, JG; Labaf, A (February 2018). <a href="javascript:if(confirm('https://zenodo.org/record/3503448  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://zenodo.org/record/3503448'" tppabs="https://zenodo.org/record/3503448" class="external text external">"Current evidence of oral anticoagulant reversal: A systematic review"</a>. <i>Thrombosis Research</i>. <b>162</b>: 22–31. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.thromres.2017.12.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.thromres.2017.12.003'" tppabs="https://doi.org/10.1016%2Fj.thromres.2017.12.003" class="external text external">10.1016/j.thromres.2017.12.003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29258056  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29258056'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29258056" class="external text external">29258056</a>.</cite></span></li><li id="cite_note-Ansell-49"> <span id="mw-reference-text-cite_note-Ansell-49" class="mw-reference-text"><cite id="CITEREFAnsellHirshHylekJacobson2008" class="citation journal cs1">Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (June 2008). <a href="javascript:if(confirm('http://journal.publications.chestnet.org/article.aspx?articleid=1085927  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://journal.publications.chestnet.org/article.aspx?articleid=1085927'" tppabs="http://journal.publications.chestnet.org/article.aspx?articleid=1085927" class="external text external">"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)"</a>. <i>Chest</i>. <b>133</b> (6 Suppl): 160S–198S. doi:<a href="javascript:if(confirm('https://doi.org/10.1378%2Fchest.08-0670  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1378%2Fchest.08-0670'" tppabs="https://doi.org/10.1378%2Fchest.08-0670" class="external text external">10.1378/chest.08-0670</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18574265  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18574265'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18574265" class="external text external">18574265</a>.</cite></span></li><li id="cite_note-pmid12186515-50"> <span id="mw-reference-text-cite_note-pmid12186515-50" class="mw-reference-text"><cite id="CITEREFCrowtherDouketisSchnurrSteidl2002" class="citation journal cs1">Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W (August 2002). "Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial". <i>Annals of Internal Medicine</i>. <b>137</b> (4): 251–4. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-137-4-200208200-00009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-137-4-200208200-00009'" tppabs="https://doi.org/10.7326%2F0003-4819-137-4-200208200-00009" class="external text external">10.7326/0003-4819-137-4-200208200-00009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12186515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12186515'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12186515" class="external text external">12186515</a>.</cite></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite id="CITEREFGageFihnWhite2000" class="citation journal cs1">Gage BF, Fihn SD, White RH (October 2000). "Management and dosing of warfarin therapy". <i>The American Journal of Medicine</i>. <b>109</b> (6): 481–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0002-9343%2800%2900545-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0002-9343%2800%2900545-3'" tppabs="https://doi.org/10.1016%2FS0002-9343%2800%2900545-3" class="external text external">10.1016/S0002-9343(00)00545-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11042238  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11042238'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11042238" class="external text external">11042238</a>.</cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><a href="javascript:if(confirm('http://www.aafp.org/afp/2000/0315/p1745.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.aafp.org/afp/2000/0315/p1745.html#sec-1'" tppabs="http://www.aafp.org/afp/2000/0315/p1745.html#sec-1" class="external text external">Clinically Significant Drug Interactions – American Family Physician</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160507065339/http://www.aafp.org/afp/2000/0315/p1745.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160507065339/http://www.aafp.org/afp/2000/0315/p1745.html'" tppabs="https://web.archive.org/web/20160507065339/http://www.aafp.org/afp/2000/0315/p1745.html" class="external text external">Archived</a><span> 7 May 2016 at the </span>Wayback Machine</span></li><li id="cite_note-Juurlink-53"> <span id="mw-reference-text-cite_note-Juurlink-53" class="mw-reference-text"><cite id="CITEREFJuurlink2007" class="citation journal cs1">Juurlink DN (August 2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942100'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942100" class="external text external">"Drug interactions with warfarin: what clinicians need to know"</a>. <i>CMAJ</i>. <b>177</b> (4): 369–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1503%2Fcmaj.070946  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1503%2Fcmaj.070946'" tppabs="https://doi.org/10.1503%2Fcmaj.070946" class="external text external">10.1503/cmaj.070946</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942100'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942100" class="external text external">1942100</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17698826  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17698826'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17698826" class="external text external">17698826</a>.</cite></span></li><li id="cite_note-Kurnik-54"> <span id="mw-reference-text-cite_note-Kurnik-54" class="mw-reference-text"><cite id="CITEREFKurnikLoebsteinFarfelEzra2004" class="citation journal cs1">Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D (March 2004). "Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland". <i>Medicine</i>. <b>83</b> (2): 107–13. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F01.md.0000123095.65294.34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F01.md.0000123095.65294.34'" tppabs="https://doi.org/10.1097%2F01.md.0000123095.65294.34" class="external text external">10.1097/01.md.0000123095.65294.34</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15028964  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15028964'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15028964" class="external text external">15028964</a>.</cite></span></li><li id="cite_note-55"> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><cite id="CITEREFStephensSelfLancasterNash1989" class="citation journal cs1">Stephens MA, Self TH, Lancaster D, Nash T (December 1989). "Hypothyroidism: effect on warfarin anticoagulation". <i>Southern Medical Journal</i>. <b>82</b> (12): 1585–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00007611-198912000-00035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00007611-198912000-00035'" tppabs="https://doi.org/10.1097%2F00007611-198912000-00035" class="external text external">10.1097/00007611-198912000-00035</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2595433  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2595433'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2595433" class="external text external">2595433</a>.</cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite id="CITEREFChuteRyanSladekShakir1997" class="citation journal cs1">Chute JP, Ryan CP, Sladek G, Shakir KM (1997). "Exacerbation of warfarin-induced anticoagulation by hyperthyroidism". <i>Endocrine Practice</i>. <b>3</b> (2): 77–9. doi:<a href="javascript:if(confirm('https://doi.org/10.4158%2FEP.3.2.77  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4158%2FEP.3.2.77'" tppabs="https://doi.org/10.4158%2FEP.3.2.77" class="external text external">10.4158/EP.3.2.77</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15251480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15251480'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15251480" class="external text external">15251480</a>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text"><cite id="CITEREFKellettSawersBoultonCholerton1986" class="citation journal cs1">Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD (January 1986). <a href="javascript:if(confirm('http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=3704105  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=3704105'" tppabs="http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=3704105" class="external text external">"Problems of anticoagulation with warfarin in hyperthyroidism"</a>. <i>The Quarterly Journal of Medicine</i>. <b>58</b> (225): 43–51. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3704105  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3704105'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3704105" class="external text external">3704105</a>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite id="CITEREFWeathermonCrabb1999" class="citation journal cs1">Weathermon R, Crabb DW (1999). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761694  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761694'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761694" class="external text external">"Alcohol and medication interactions"</a>. <i>Alcohol Research &amp; Health</i>. <b>23</b> (1): 40–54. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761694  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761694'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761694" class="external text external">6761694</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10890797  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10890797'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10890797" class="external text external">10890797</a>.</cite></span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text"><a href="javascript:if(confirm('https://my.clevelandclinic.org/health/drugs/16182-warfarin-a-blood-thinning-drug-what-you-need-to-know-  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://my.clevelandclinic.org/health/drugs/16182-warfarin-a-blood-thinning-drug-what-you-need-to-know-'" tppabs="https://my.clevelandclinic.org/health/drugs/16182-warfarin-a-blood-thinning-drug-what-you-need-to-know-" class="external autonumber external"></a></span></li><li id="cite_note-drug-herb-60"> <span id="mw-reference-text-cite_note-drug-herb-60" class="mw-reference-text"><cite id="CITEREFAustinBatz1999" class="citation book cs1">Austin S, Batz F (1999).  Lininger SW (ed.). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://archive.org/details/azguidetodrugher0000unse/page/224  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/azguidetodrugher0000unse/page/224'" tppabs="https://archive.org/details/azguidetodrugher0000unse/page/224" class="external text external"><i>A-Z guide to drug-herb-vitamin interactions: how to improve your health and avoid problems when using common medications and natural supplements together</i></a></span>. Roseville, Calif: Prima Health. p.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/azguidetodrugher0000unse/page/224  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/azguidetodrugher0000unse/page/224'" tppabs="https://archive.org/details/azguidetodrugher0000unse/page/224" class="external text external">224</a>. ISBN<span>&nbsp;</span><bdi>978-0-7615-1599-9</bdi>.</cite></span></li><li id="cite_note-61"> <span id="mw-reference-text-cite_note-61" class="mw-reference-text"><cite id="CITEREFHeckDeWittLukes2000" class="citation journal cs1">Heck, A. M.; DeWitt, B. A.; Lukes, A. L. (1 July 2000). <a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10902065/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10902065/'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10902065/" class="external text external">"Potential interactions between alternative therapies and warfarin"</a>. <i>American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists</i>. <b>57</b> (13): 1221–1227, quiz 1228–1230. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1079-2082  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1079-2082'" tppabs="https://www.worldcat.org/issn/1079-2082" class="external text external">1079-2082</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10902065  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10902065'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10902065" class="external text external">10902065</a>.</cite></span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text"><cite id="CITEREFBarnesWorking_Group_on_Complementary_Medicine2002" class="citation web cs1">Barnes J, Working Group on Complementary Medicine (September 2002). <a href="javascript:if(confirm('https://web.archive.org/web/20060924184428/http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060924184428/http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf'" tppabs="https://web.archive.org/web/20060924184428/http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf" class="external text external">"Herb-medicine interactions: St John's Wort (Hypericum perforatum) Useful information for pharmacist"</a> <span class="cs1-format">(PDF)</span>. 1 Lambeth High Street, London SE1 7JN: Royal Pharmaceutical Society of Great Britain. p.<span>&nbsp;</span>5. Archived from <a href="javascript:if(confirm('http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf'" tppabs="http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 24 September 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">14 January</span> 2009</span>.</cite><span class="cs1-maint citation-comment">CS1 maint: location (link)</span></span></li><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://news.bbc.co.uk/1/hi/health/3120206.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bbc.co.uk/1/hi/health/3120206.stm'" tppabs="http://news.bbc.co.uk/1/hi/health/3120206.stm" class="external text external">"Cranberry juice clot drug warning"</a>. <i>BBC news</i>. 18 September 2003. <a href="javascript:if(confirm('https://web.archive.org/web/20080209212613/http://news.bbc.co.uk/1/hi/health/3120206.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080209212613/http://news.bbc.co.uk/1/hi/health/3120206.stm'" tppabs="https://web.archive.org/web/20080209212613/http://news.bbc.co.uk/1/hi/health/3120206.stm" class="external text external">Archived</a> from the original on 9 February 2008<span class="reference-accessdate">. Retrieved <span class="nowrap">18 May</span> 2008</span>.</cite></span></li><li id="cite_note-Suvarna-64"> <span id="mw-reference-text-cite_note-Suvarna-64" class="mw-reference-text"><cite id="CITEREFSuvarnaPirmohamedHenderson2003" class="citation journal cs1">Suvarna R, Pirmohamed M, Henderson L (December 2003). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300803  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300803'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300803" class="external text external">"Possible interaction between warfarin and cranberry juice"</a>. <i>BMJ</i>. <b>327</b> (7429): 1454. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.327.7429.1454  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.327.7429.1454'" tppabs="https://doi.org/10.1136%2Fbmj.327.7429.1454" class="external text external">10.1136/bmj.327.7429.1454</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300803  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300803'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300803" class="external text external">300803</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14684645  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14684645'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14684645" class="external text external">14684645</a>.</cite></span></li><li id="cite_note-Aston-65"> <span id="mw-reference-text-cite_note-Aston-65" class="mw-reference-text"><cite id="CITEREFAstonLodolceShapiro2006" class="citation journal cs1">Aston JL, Lodolce AE, Shapiro NL (September 2006). "Interaction between warfarin and cranberry juice". <i>Pharmacotherapy</i>. <b>26</b> (9): 1314–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1592%2Fphco.26.9.1314  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1592%2Fphco.26.9.1314'" tppabs="https://doi.org/10.1592%2Fphco.26.9.1314" class="external text external">10.1592/phco.26.9.1314</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16945054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16945054'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16945054" class="external text external">16945054</a>.</cite><a href="javascript:if(confirm('http://www.medscape.com/viewarticle/545631  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.com/viewarticle/545631'" tppabs="http://www.medscape.com/viewarticle/545631" class="external text external">Free full text with registration at Medscape</a> <a href="javascript:if(confirm('https://web.archive.org/web/20101109014448/http://www.medscape.com/viewarticle/545631  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101109014448/http://www.medscape.com/viewarticle/545631'" tppabs="https://web.archive.org/web/20101109014448/http://www.medscape.com/viewarticle/545631" class="external text external">Archived</a><span> 9 November 2010 at the </span>Wayback Machine</span></li><li id="cite_note-Pham-66"> <span id="mw-reference-text-cite_note-Pham-66" class="mw-reference-text"><cite id="CITEREFPhamPham2007" class="citation journal cs1">Pham DQ, Pham AQ (March 2007). "Interaction potential between cranberry juice and warfarin". <i>American Journal of Health-System Pharmacy</i>. <b>64</b> (5): 490–4. doi:<a href="javascript:if(confirm('https://doi.org/10.2146%2Fajhp060370  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2146%2Fajhp060370'" tppabs="https://doi.org/10.2146%2Fajhp060370" class="external text external">10.2146/ajhp060370</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17322161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17322161'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17322161" class="external text external">17322161</a>.</cite></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text"><cite id="CITEREFValenteTragerJensen1975" class="citation journal cs1">Valente EJ, Trager WF, Jensen LH (1975). <a href="javascript:if(confirm('http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs'" tppabs="http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs" class="external text external">"The crystal and molecular structure and absolute configuration of (−)-(<i>S</i>)-warfarin"</a>. <i>Acta Crystallogr. B</i>. <b>31</b> (4): 954–960. doi:<a href="javascript:if(confirm('https://doi.org/10.1107%2FS056774087500427X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1107%2FS056774087500427X'" tppabs="https://doi.org/10.1107%2FS056774087500427X" class="external text external">10.1107/S056774087500427X</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20151020103015/http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151020103015/http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs'" tppabs="https://web.archive.org/web/20151020103015/http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs" class="external text external">Archived</a> from the original on 20 October 2015.</cite></span></li><li id="cite_note-pmid17691835-68"> <span id="mw-reference-text-cite_note-pmid17691835-68" class="mw-reference-text"><cite id="CITEREFKarlssonRosengrenAnderssonNicholls2007" class="citation journal cs1">Karlsson BC, Rosengren AM, Andersson PO, Nicholls IA (September 2007). <a href="javascript:if(confirm('https://figshare.com/articles/The_Spectrophysics_of_Warfarin_Implications_for_Protein_Binding/2986813  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://figshare.com/articles/The_Spectrophysics_of_Warfarin_Implications_for_Protein_Binding/2986813'" tppabs="https://figshare.com/articles/The_Spectrophysics_of_Warfarin_Implications_for_Protein_Binding/2986813" class="external text external">"The spectrophysics of warfarin: implications for protein binding"</a>. <i>The Journal of Physical Chemistry B</i>. <b>111</b> (35): 10520–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjp072505i  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjp072505i'" tppabs="https://doi.org/10.1021%2Fjp072505i" class="external text external">10.1021/jp072505i</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17691835  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17691835'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17691835" class="external text external">17691835</a>.</cite></span></li><li id="cite_note-Rote_Liste-69"> <span id="mw-reference-text-cite_note-Rote_Liste-69" class="mw-reference-text"><cite class="citation book cs1"><i>Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte)</i>. Frankfurt/Main: Rote Liste Service GmbH. 2017. p.<span>&nbsp;</span>226. ISBN<span>&nbsp;</span><bdi>978-3-946057-10-9</bdi>.</cite></span></li><li id="cite_note-70"> <span id="mw-reference-text-cite_note-70" class="mw-reference-text"><cite id="CITEREFShaikGraterLullaWilliams2016" class="citation journal cs1">Shaik AN, Grater R, Lulla M, Williams DA, Gan LL, Bohnert T, LeDuc BW (January 2016). "Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry". <i>Journal of Chromatography B</i>. <b>1008</b> (1): 164–173. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jchromb.2015.11.036  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jchromb.2015.11.036'" tppabs="https://doi.org/10.1016%2Fj.jchromb.2015.11.036" class="external text external">10.1016/j.jchromb.2015.11.036</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26655108  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26655108'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26655108" class="external text external">26655108</a>.</cite></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><a href="javascript:if(confirm('https://www.google.com/books/edition/X_Ray_Vision/UtA8BAAAQBAJ?hl=en&gbpv=1&dq=warfarin+blood+thinner+misnomer&pg=PA138&printsec=frontcover  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.google.com/books/edition/X_Ray_Vision/UtA8BAAAQBAJ?hl=en&gbpv=1&dq=warfarin+blood+thinner+misnomer&pg=PA138&printsec=frontcover'" tppabs="https://www.google.com/books/edition/X_Ray_Vision/UtA8BAAAQBAJ?hl=en&gbpv=1&dq=warfarin+blood+thinner+misnomer&pg=PA138&printsec=frontcover" class="external autonumber external"></a></span></li><li id="cite_note-72"> <span id="mw-reference-text-cite_note-72" class="mw-reference-text"><cite id="CITEREFFreedman1992" class="citation journal cs1">Freedman MD (March 1992). "Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects". <i>Journal of Clinical Pharmacology</i>. <b>32</b> (3): 196–209. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fj.1552-4604.1992.tb03827.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fj.1552-4604.1992.tb03827.x'" tppabs="https://doi.org/10.1002%2Fj.1552-4604.1992.tb03827.x" class="external text external">10.1002/j.1552-4604.1992.tb03827.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1564123  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1564123'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1564123" class="external text external">1564123</a>.</cite></span></li><li id="cite_note-Whitlon-73"> <span id="mw-reference-text-cite_note-Whitlon-73" class="mw-reference-text"><cite id="CITEREFWhitlonSadowskiSuttie1978" class="citation journal cs1">Whitlon DS, Sadowski JA, Suttie JW (April 1978). "Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition". <i>Biochemistry</i>. <b>17</b> (8): 1371–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fbi00601a003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fbi00601a003'" tppabs="https://doi.org/10.1021%2Fbi00601a003" class="external text external">10.1021/bi00601a003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/646989  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/646989'" tppabs="https://pubmed.ncbi.nlm.nih.gov/646989" class="external text external">646989</a>.</cite></span></li><li id="cite_note-74"> <span id="mw-reference-text-cite_note-74" class="mw-reference-text"><cite id="CITEREFLiChangJinLin2004" class="citation journal cs1">Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (February 2004). "Identification of the gene for vitamin K epoxide reductase". <i>Nature</i>. <b>427</b> (6974): 541–4. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2004Natur.427..541L  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2004Natur.427..541L'" tppabs="https://ui.adsabs.harvard.edu/abs/2004Natur.427..541L" class="external text external">2004Natur.427..541L</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature02254  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature02254'" tppabs="https://doi.org/10.1038%2Fnature02254" class="external text external">10.1038/nature02254</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14765195  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14765195'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14765195" class="external text external">14765195</a>.</cite></span></li><li id="cite_note-pmid14765194-75"> <span id="mw-reference-text-cite_note-pmid14765194-75" class="mw-reference-text"><cite id="CITEREFRostFreginIvaskeviciusConzelmann2004" class="citation journal cs1">Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J (February 2004). "Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2". <i>Nature</i>. <b>427</b> (6974): 537–41. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2004Natur.427..537R  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2004Natur.427..537R'" tppabs="https://ui.adsabs.harvard.edu/abs/2004Natur.427..537R" class="external text external">2004Natur.427..537R</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature02214  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature02214'" tppabs="https://doi.org/10.1038%2Fnature02214" class="external text external">10.1038/nature02214</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14765194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14765194'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14765194" class="external text external">14765194</a>.</cite></span></li><li id="cite_note-76"> <span id="mw-reference-text-cite_note-76" class="mw-reference-text"><cite id="CITEREFLitinGastineau1995" class="citation journal cs1">Litin SC, Gastineau DA (March 1995). <a href="javascript:if(confirm('https://doi.org/10.4065/70.3.266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4065/70.3.266'" tppabs="https://doi.org/10.4065/70.3.266" class="external text external">"Current concepts in anticoagulant therapy"</a>. <i>Mayo Clinic Proceedings</i>. <b>70</b> (3): 266–72. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.4065%2F70.3.266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4065%2F70.3.266'" tppabs="https://doi.org/10.4065%2F70.3.266" class="external text external">10.4065/70.3.266</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7861815  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7861815'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7861815" class="external text external">7861815</a>.</cite></span></li><li id="cite_note-77"> <span id="mw-reference-text-cite_note-77" class="mw-reference-text"><cite id="CITEREFWittkowsky2005" class="citation journal cs1">Wittkowsky AK (2005). "Why warfarin and heparin need to overlap when treating acute venous thromboembolism". <i>Disease-A-Month</i>. <b>51</b> (2–3): 112–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.disamonth.2005.03.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.disamonth.2005.03.005'" tppabs="https://doi.org/10.1016%2Fj.disamonth.2005.03.005" class="external text external">10.1016/j.disamonth.2005.03.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15900262  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15900262'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15900262" class="external text external">15900262</a>.</cite></span></li><li id="cite_note-pmid15883587-78"> <span id="mw-reference-text-cite_note-pmid15883587-78" class="mw-reference-text"><cite id="CITEREFWadeliusChenDownesGhori2005" class="citation journal cs1">Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P (2005). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.tpj.6500313  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.tpj.6500313'" tppabs="https://doi.org/10.1038/sj.tpj.6500313" class="external text external">"Common VKORC1 and GGCX polymorphisms associated with warfarin dose"</a>. <i>The Pharmacogenomics Journal</i>. <b>5</b> (4): 262–70. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.tpj.6500313  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.tpj.6500313'" tppabs="https://doi.org/10.1038%2Fsj.tpj.6500313" class="external text external">10.1038/sj.tpj.6500313</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15883587  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15883587'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15883587" class="external text external">15883587</a>.</cite></span></li><li id="cite_note-pmid15930419-79"> <span id="mw-reference-text-cite_note-pmid15930419-79" class="mw-reference-text"><cite id="CITEREFRiederReinerGageNickerson2005" class="citation journal cs1">Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (June 2005). "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose". <i>The New England Journal of Medicine</i>. <b>352</b> (22): 2285–93. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa044503  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa044503'" tppabs="https://doi.org/10.1056%2FNEJMoa044503" class="external text external">10.1056/NEJMoa044503</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15930419  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15930419'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15930419" class="external text external">15930419</a>.</cite></span></li><li id="cite_note-pmid18322281-80"> <span id="mw-reference-text-cite_note-pmid18322281-80" class="mw-reference-text"><cite id="CITEREFSchwarzRitchieBradfordLi2008" class="citation journal cs1">Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (March 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894627  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894627'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894627" class="external text external">"Genetic determinants of response to warfarin during initial anticoagulation"</a>. <i>The New England Journal of Medicine</i>. <b>358</b> (10): 999–1008. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa0708078  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa0708078'" tppabs="https://doi.org/10.1056%2FNEJMoa0708078" class="external text external">10.1056/NEJMoa0708078</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894627  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894627'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894627" class="external text external">3894627</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18322281  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18322281'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18322281" class="external text external">18322281</a>.</cite></span></li><li id="cite_note-pmid15714076-81"> <span id="mw-reference-text-cite_note-pmid15714076-81" class="mw-reference-text"><cite id="CITEREFSandersonEmeryHiggins2005" class="citation journal cs1">Sanderson S, Emery J, Higgins J (February 2005). <a href="javascript:if(confirm('https://doi.org/10.1097/01.GIM.0000153664.65759.CF  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097/01.GIM.0000153664.65759.CF'" tppabs="https://doi.org/10.1097/01.GIM.0000153664.65759.CF" class="external text external">"CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis"</a>. <i>Genetics in Medicine</i>. <b>7</b> (2): 97–104. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1097%2F01.GIM.0000153664.65759.CF  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F01.GIM.0000153664.65759.CF'" tppabs="https://doi.org/10.1097%2F01.GIM.0000153664.65759.CF" class="external text external">10.1097/01.GIM.0000153664.65759.CF</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15714076  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15714076'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15714076" class="external text external">15714076</a>.</cite></span></li><li id="cite_note-82"> <span id="mw-reference-text-cite_note-82" class="mw-reference-text"><cite id="CITEREFJensenJacquesCiccantiLong2009" class="citation web cs1">Jensen TS, Jacques LB, Ciccanti M, Long K, Eggleston L, Roche J (3 August 2009). <a href="javascript:if(confirm('https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15'" tppabs="https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15" class="external text external">"Decision Memo for Pharmacogenomic Testing for Warfarin Response (CAG-00400N)"</a>. Centers for Medicare and Medicaid Services. <a href="javascript:if(confirm('https://web.archive.org/web/20180414233940/https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20180414233940/https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15'" tppabs="https://web.archive.org/web/20180414233940/https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15" class="external text external">Archived</a> from the original on 14 April 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2018</span>.</cite></span></li><li id="cite_note-Stergiopoulos-83"> <span id="mw-reference-text-cite_note-Stergiopoulos-83" class="mw-reference-text"><cite id="CITEREFStergiopoulosBrown2014" class="citation journal cs1">Stergiopoulos K, Brown DL (August 2014). <a href="javascript:if(confirm('https://doi.org/10.1001/jamainternmed.2014.2368  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/jamainternmed.2014.2368'" tppabs="https://doi.org/10.1001/jamainternmed.2014.2368" class="external text external">"Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials"</a>. <i>JAMA Internal Medicine</i>. <b>174</b> (8): 1330–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Fjamainternmed.2014.2368  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjamainternmed.2014.2368'" tppabs="https://doi.org/10.1001%2Fjamainternmed.2014.2368" class="external text external">10.1001/jamainternmed.2014.2368</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24935087  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24935087'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24935087" class="external text external">24935087</a>.</cite></span></li><li id="cite_note-Distillations-84"> <span id="mw-reference-text-cite_note-Distillations-84" class="mw-reference-text"><cite id="CITEREFRajagopalan2018" class="citation journal cs1">Rajagopalan, Ramya (2018). <a href="javascript:if(confirm('https://www.sciencehistory.org/distillations/magazine/a-study-in-scarlet  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sciencehistory.org/distillations/magazine/a-study-in-scarlet'" tppabs="https://www.sciencehistory.org/distillations/magazine/a-study-in-scarlet" class="external text external">"A Study in Scarlet"</a>. <i>Distillations</i>. <b>4</b> (1): 26–35<span class="reference-accessdate">. Retrieved <span class="nowrap">27 June</span> 2018</span>.</cite></span></li><li id="cite_note-Laurence_1973_23.4-23.5-85"> <span id="mw-reference-text-cite_note-Laurence_1973_23.4-23.5-85" class="mw-reference-text"><cite id="CITEREFLaurenceKneebone1973" class="citation book cs1">Laurence DR, Kneebone P (1973). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://archive.org/details/clinicalpharmaco0000laur  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/clinicalpharmaco0000laur'" tppabs="https://archive.org/details/clinicalpharmaco0000laur" class="external text external"><i>Clinical Pharmacology</i></a></span>. Edinburgh, London and New York: Churchill Livingstone. pp.<span>&nbsp;</span>23.4–23.5. ISBN<span>&nbsp;</span><bdi>978-0-443-04990-3</bdi>.</cite></span></li><li id="cite_note-86"> <span id="mw-reference-text-cite_note-86" class="mw-reference-text"><cite id="CITEREFSchofield_FW1924" class="citation journal cs1">Schofield FW (1924). "Damaged sweet clover; the cause of a new disease in cattle simulating haemorrhagic septicemia and blackleg". <i>J Am Vet Med Assoc</i>. <b>64</b>: 553–6.</cite></span></li><li id="cite_note-87"> <span id="mw-reference-text-cite_note-87" class="mw-reference-text"><cite id="CITEREFRoderick_LM1931" class="citation journal cs1">Roderick LM (1931). "A problem in the coagulation of the blood; "sweet clover disease of the cattle<span class="cs1-kern-right">"</span>". <i>Am J Physiol</i>. <b>96</b> (2): 413–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1152%2Fajplegacy.1931.96.2.413  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1152%2Fajplegacy.1931.96.2.413'" tppabs="https://doi.org/10.1152%2Fajplegacy.1931.96.2.413" class="external text external">10.1152/ajplegacy.1931.96.2.413</a>.</cite><a href="javascript:if(confirm('http://ajplegacy.physiology.org/cgi/reprint/96/2/413  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ajplegacy.physiology.org/cgi/reprint/96/2/413'" tppabs="http://ajplegacy.physiology.org/cgi/reprint/96/2/413" class="external text external">PDF (subscriber only)</a> <a href="javascript:if(confirm('https://web.archive.org/web/20071013150832/http://ajplegacy.physiology.org/cgi/reprint/96/2/413  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20071013150832/http://ajplegacy.physiology.org/cgi/reprint/96/2/413'" tppabs="https://web.archive.org/web/20071013150832/http://ajplegacy.physiology.org/cgi/reprint/96/2/413" class="external text external">Archived</a><span> 13 October 2007 at the </span>Wayback Machine.</span></li><li id="cite_note-88"> <span id="mw-reference-text-cite_note-88" class="mw-reference-text"><cite id="CITEREFStahmannHuebnerLink1941" class="citation journal cs1">Stahmann MA, Huebner CF, Link KP (1 April 1941). <a href="javascript:if(confirm('http://www.jbc.org/cgi/reprint/138/2/513  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jbc.org/cgi/reprint/138/2/513'" tppabs="http://www.jbc.org/cgi/reprint/138/2/513" class="external text external">"Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent"</a>. <i>J Biol Chem</i>. <b>138</b> (2): 513–27. <a href="javascript:if(confirm('https://web.archive.org/web/20090627063001/http://www.jbc.org/cgi/reprint/138/2/513  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090627063001/http://www.jbc.org/cgi/reprint/138/2/513'" tppabs="https://web.archive.org/web/20090627063001/http://www.jbc.org/cgi/reprint/138/2/513" class="external text external">Archived</a> from the original on 27 June 2009.</cite></span></li><li id="cite_note-Bye_1970-89"> <span id="mw-reference-text-cite_note-Bye_1970-89" class="mw-reference-text"><cite id="CITEREFByeKing1970" class="citation journal cs1">Bye A, King HK (April 1970). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1178855  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1178855'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1178855" class="external text external">"The biosynthesis of 4-hydroxycoumarin and dicoumarol by Aspergillus fumigatus Fresenius"</a>. <i>The Biochemical Journal</i>. <b>117</b> (2): 237–45. doi:<a href="javascript:if(confirm('https://doi.org/10.1042%2Fbj1170237  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1042%2Fbj1170237'" tppabs="https://doi.org/10.1042%2Fbj1170237" class="external text external">10.1042/bj1170237</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1178855  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1178855'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1178855" class="external text external">1178855</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4192639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4192639'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4192639" class="external text external">4192639</a>.</cite></span></li><li id="cite_note-pmid13619027-90"> <span id="mw-reference-text-cite_note-pmid13619027-90" class="mw-reference-text"><cite id="CITEREFLink1959" class="citation journal cs1">Link KP (January 1959). <a href="javascript:if(confirm('https://doi.org/10.1161/01.CIR.19.1.97  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161/01.CIR.19.1.97'" tppabs="https://doi.org/10.1161/01.CIR.19.1.97" class="external text external">"The discovery of dicumarol and its sequels"</a>. <i>Circulation</i>. <b>19</b> (1): 97–107. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1161%2F01.CIR.19.1.97  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161%2F01.CIR.19.1.97'" tppabs="https://doi.org/10.1161%2F01.CIR.19.1.97" class="external text external">10.1161/01.CIR.19.1.97</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/13619027  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/13619027'" tppabs="https://pubmed.ncbi.nlm.nih.gov/13619027" class="external text external">13619027</a>.</cite></span></li><li id="cite_note-91"> <span id="mw-reference-text-cite_note-91" class="mw-reference-text"><cite id="CITEREFNaumovBrent2003" class="citation book cs1">Naumov VP, Brent J (2003). <i>Stalin's last crime: the plot against the Jewish doctors, 1948–1953</i>. London: HarperCollins. ISBN<span>&nbsp;</span><bdi>978-0-06-019524-3</bdi>.</cite></span></li><li id="cite_note-92"> <span id="mw-reference-text-cite_note-92" class="mw-reference-text"><cite id="CITEREFUnited_States_Occupational_Safety_and_Health_Administration_(OSHA)1996" class="citation web cs1">United States Occupational Safety and Health Administration (OSHA) (16 August 1996). <a href="javascript:if(confirm('https://www.cdc.gov/niosh/idlh/81812.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cdc.gov/niosh/idlh/81812.html'" tppabs="https://www.cdc.gov/niosh/idlh/81812.html" class="external text external">"Documentation for Immediately Dangerous To Life or Health Concentrations (IDLHs): Warfarin"</a>. Centers for Disease Control and Prevention. <a href="javascript:if(confirm('https://web.archive.org/web/20080726031247/http://www.cdc.gov/niosh/idlh/81812.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080726031247/http://www.cdc.gov/niosh/idlh/81812.html'" tppabs="https://web.archive.org/web/20080726031247/http://www.cdc.gov/niosh/idlh/81812.html" class="external text external">Archived</a> from the original on 26 July 2008<span class="reference-accessdate">. Retrieved <span class="nowrap">7 July</span> 2008</span>.</cite></span></li><li id="cite_note-NZToxins-93"> <span id="mw-reference-text-cite_note-NZToxins-93" class="mw-reference-text"><cite id="CITEREFEasonWickstrom2001" class="citation book cs1">Eason CT, Wickstrom M (2001). <a href="javascript:if(confirm('http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf'" tppabs="http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf" class="external text external">"2. Anticoagulant poisons"</a> <span class="cs1-format">(PDF)</span>. <i>Vertebrate pesticide toxicology manual (poisons)</i>. New Zealand Department of Conservation. pp.<span>&nbsp;</span>41–74. ISBN<span>&nbsp;</span><bdi>978-0-478-22035-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20081017022833/http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20081017022833/http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf'" tppabs="https://web.archive.org/web/20081017022833/http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 17 October 2008.</cite></span></li><li id="cite_note-94"> <span id="mw-reference-text-cite_note-94" class="mw-reference-text"><cite id="CITEREFLovett2012" class="citation news cs1">Lovett RA (14 November 2012). <a href="javascript:if(confirm('http://www.nature.com/news/killing-rats-is-killing-birds-1.11824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nature.com/news/killing-rats-is-killing-birds-1.11824'" tppabs="http://www.nature.com/news/killing-rats-is-killing-birds-1.11824" class="external text external">"Killing rats is killing birds"</a>. <i>Nature</i>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature.2012.11824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature.2012.11824'" tppabs="https://doi.org/10.1038%2Fnature.2012.11824" class="external text external">10.1038/nature.2012.11824</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20150426133605/http://www.nature.com/news/killing-rats-is-killing-birds-1.11824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150426133605/http://www.nature.com/news/killing-rats-is-killing-birds-1.11824'" tppabs="https://web.archive.org/web/20150426133605/http://www.nature.com/news/killing-rats-is-killing-birds-1.11824" class="external text external">Archived</a> from the original on 26 April 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">5 April</span> 2015</span>.</cite></span></li><li id="cite_note-Johnson_2014-95"> <span id="mw-reference-text-cite_note-Johnson_2014-95" class="mw-reference-text"><cite id="CITEREFJohnsonAréchiga-CeballosAguilar-Setien2014" class="citation journal cs1">Johnson N, Aréchiga-Ceballos N, Aguilar-Setien A (April 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036541  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036541'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036541" class="external text external">"Vampire bat rabies: ecology, epidemiology and control"</a>. <i>Viruses</i>. <b>6</b> (5): 1911–28. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fv6051911  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fv6051911'" tppabs="https://doi.org/10.3390%2Fv6051911" class="external text external">10.3390/v6051911</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036541  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036541'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036541" class="external text external">4036541</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24784570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24784570'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24784570" class="external text external">24784570</a>.</cite></span></li><li id="cite_note-Streicker_2012-96"> <span id="mw-reference-text-cite_note-Streicker_2012-96" class="mw-reference-text"><cite id="CITEREFStreickerRecuencoValderramaGomez_Benavides2012" class="citation journal cs1">Streicker DG, Recuenco S, Valderrama W, Gomez Benavides J, Vargas I, Pacheco V, Condori Condori RE, Montgomery J, Rupprecht CE, Rohani P, Altizer S (September 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396893  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396893'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396893" class="external text external">"Ecological and anthropogenic drivers of rabies exposure in vampire bats: implications for transmission and control"</a>. <i>Proceedings: Biological Sciences</i>. <b>279</b> (1742): 3384–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1098%2Frspb.2012.0538  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1098%2Frspb.2012.0538'" tppabs="https://doi.org/10.1098%2Frspb.2012.0538" class="external text external">10.1098/rspb.2012.0538</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396893  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396893'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396893" class="external text external">3396893</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22696521  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22696521'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22696521" class="external text external">22696521</a>.</cite></span></li><li id="cite_note-97"> <span id="mw-reference-text-cite_note-97" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cdc.gov/niosh/npg/npgd0665.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cdc.gov/niosh/npg/npgd0665.html'" tppabs="https://www.cdc.gov/niosh/npg/npgd0665.html" class="external text external">"CDC – NIOSH Pocket Guide to Chemical Hazards – Warfarin"</a>. <i>www.cdc.gov</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20151208093728/http://www.cdc.gov/niosh/npg/npgd0665.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151208093728/http://www.cdc.gov/niosh/npg/npgd0665.html'" tppabs="https://web.archive.org/web/20151208093728/http://www.cdc.gov/niosh/npg/npgd0665.html" class="external text external">Archived</a> from the original on 8 December 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">27 November</span> 2015</span>.</cite></span></li><li id="cite_note-gov-right-know-98"> <span id="mw-reference-text-cite_note-gov-right-know-98" class="mw-reference-text"><cite class="citation journal cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120225051612/http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120225051612/http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf'" tppabs="https://web.archive.org/web/20120225051612/http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf" class="external text external">"40 C.F.R.: Appendix A to Part 355—The List of Extremely Hazardous Substances and Their Threshold Planning Quantities"</a> <span class="cs1-format">(PDF)</span> (1 July 2008 ed.). Government Printing Office. Archived from <a href="javascript:if(confirm('http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf'" tppabs="http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 25 February 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">29 October</span> 2011</span>.</cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFDean2012" class="citation book cs1">Dean L (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK84174/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK84174/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK84174/" class="external text external">"Warfarin Therapy and VKORC1 and CYP Genotype"</a>.  In Pratt VM, McLeod HL, Rubinstein WS,  et al. (eds.). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK61999/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK61999/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK61999/" class="external text external"><i>Medical Genetics Summaries</i></a>. National Center for Biotechnology Information (NCBI). PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28520347  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28520347'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28520347" class="external text external">28520347</a>. Bookshelf ID: NBK84174.</cite></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/warfarin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/warfarin'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/warfarin" class="external text external">"Warfarin"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><a href="javascript:if(confirm('http://www.warf.org/about/index.jsp?cid=26&scid=34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.warf.org/about/index.jsp?cid=26&scid=34'" tppabs="http://www.warf.org/about/index.jsp?cid=26&scid=34" class="external text external">Historical information on warfarin</a> from the Wisconsin Alumni Research Foundation</li>
<li><a href="javascript:if(confirm('http://www.jbc.org/content/280/8/e5.full  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jbc.org/content/280/8/e5.full'" tppabs="http://www.jbc.org/content/280/8/e5.full" class="external text external">Online sweet clover disease and warfarin historical review</a></li>
<li>Warfarin bound to proteins in the PDB:  <a href="javascript:if(confirm('http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RWF  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RWF'" tppabs="http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RWF" class="external text external">R-warfarin</a>, <a href="javascript:if(confirm('http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=SWF  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=SWF'" tppabs="http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=SWF" class="external text external">S-warfarin</a></li>
<li><a href="javascript:if(confirm('https://www.cdc.gov/niosh/npg/npgd0665.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cdc.gov/niosh/npg/npgd0665.html'" tppabs="https://www.cdc.gov/niosh/npg/npgd0665.html" class="external text external">CDC – NIOSH Pocket Guide to Chemical Hazards</a></li>
<li><i><a href="javascript:if(confirm('http://sitem.herts.ac.uk/aeru/ppdb/en/Reports/681.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://sitem.herts.ac.uk/aeru/ppdb/en/Reports/681.htm'" tppabs="http://sitem.herts.ac.uk/aeru/ppdb/en/Reports/681.htm" class="external text external">Warfarin</a></i><span> in the Pesticide Properties DataBase (PPDB)</span></li>
<li><a href="javascript:if(confirm('https://www.healthstandnutrition.com/wp-content/uploads/2011/09/Eating-guidelines-for-people-taking-warfaring-anticoagulants.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.healthstandnutrition.com/wp-content/uploads/2011/09/Eating-guidelines-for-people-taking-warfaring-anticoagulants.pdf'" tppabs="https://www.healthstandnutrition.com/wp-content/uploads/2011/09/Eating-guidelines-for-people-taking-warfaring-anticoagulants.pdf" class="external text external">Eating guidelines for people taking warfarin anti-coagulant(coudamin)</a></li></ul>

<p><b>Bleeding risk calculators</b></p>
<ul><li><a href="javascript:if(confirm('http://www.mdcalc.com/atria-bleeding-risk-score/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mdcalc.com/atria-bleeding-risk-score/'" tppabs="http://www.mdcalc.com/atria-bleeding-risk-score/" class="external text external">ATRIA Bleeding Risk Score</a> from MDCalc</li>
<li><a href="javascript:if(confirm('http://www.mdcalc.com/has-bled-score-for-major-bleeding-risk/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mdcalc.com/has-bled-score-for-major-bleeding-risk/'" tppabs="http://www.mdcalc.com/has-bled-score-for-major-bleeding-risk/" class="external text external">HAS-BLED Score</a> from MDCalc</li></ul>
<div style="clear:both;"></div>

<div role="navigation" class="navbox" aria-labelledby="Antithrombotics_(thrombolytics,_anticoagulants_and_antiplatelet_drugs)_(B01)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antithrombotics_(thrombolytics,_anticoagulants_and_antiplatelet_drugs)_(B01)" style="font-size:114%;margin:0 4em">Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antiplatelet drugs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Glycoprotein IIb/IIIa inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Abciximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Abciximab" title="Abciximab">Abciximab</a></li>
<li><a href="Eptifibatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Eptifibatide" title="Eptifibatide">Eptifibatide</a></li>
<li><span class="new">Orbofiban</span></li>
<li><span class="new">Roxifiban</span></li>
<li>Sibrafiban<sup>§</sup></li>
<li><a href="Tirofiban.htm" tppabs="https://ptable.com/wiki/compounds/A/Tirofiban" title="Tirofiban">Tirofiban</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">ADP receptor/P2Y<sub>12</sub> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thienopyridines
<ul><li><a href="Clopidogrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Clopidogrel" title="Clopidogrel">Clopidogrel</a></li>
<li>Prasugrel</li>
<li><a href="Ticlopidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ticlopidine" title="Ticlopidine">Ticlopidine</a></li></ul></li>
<li>Nucleotide/nucleoside analogs
<ul><li>Cangrelor</li>
<li>Elinogrel</li>
<li>Ticagrelor</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Prostaglandin analogue (<a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">PGI2</a>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Beraprost</li>
<li><a href="Iloprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Iloprost" title="Iloprost">Iloprost</a></li>
<li><a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">Prostacyclin</a></li>
<li><a href="Treprostinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Treprostinil" title="Treprostinil">Treprostinil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">COX inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Acetylsalicylic acid/Aspirin</a><sup>#</sup></li>
<li>Aloxiprin</li>
<li>Carbasalate calcium</li>
<li>Indobufen</li>
<li>Triflusal</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thromboxane inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thromboxane synthase inhibitors
<ul><li><a href="Dipyridamole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyridamole" title="Dipyridamole">Dipyridamole</a> (+ aspirin)</li>
<li><a href="Picotamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Picotamide" title="Picotamide">Picotamide</a></li>
<li>Terbogrel</li></ul></li>
<li>Receptor antagonists
<ul><li>Terbogrel</li>
<li>Terutroban<sup>§</sup></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Phosphodiesterase inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Cilostazol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cilostazol" title="Cilostazol">Cilostazol</a></li>
<li><a href="Dipyridamole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyridamole" title="Dipyridamole">Dipyridamole</a></li>
<li>Triflusal</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cloricromen</li>
<li>Ditazole</li>
<li>Vorapaxar</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anticoagulants</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Vitamin K antagonists<br>(inhibit <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Thrombin" title="Thrombin">II</a>, VII, IX, X)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">Coumarins</a>: <a href="Acenocoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Acenocoumarol" title="Acenocoumarol">Acenocoumarol</a></li>
<li><a href="Coumatetralyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumatetralyl" title="Coumatetralyl">Coumatetralyl</a></li>
<li><a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">Dicoumarol</a></li>
<li>Ethyl biscoumacetate</li>
<li><a href="Phenprocoumon.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenprocoumon" title="Phenprocoumon">Phenprocoumon</a></li>
<li><a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">Warfarin</a><sup>#</sup></li>
<li><a href="1,3-Indandione.htm" tppabs="https://ptable.com/wiki/compounds/A/1%2C3-Indandione" title="1,3-Indandione">1,3-Indandiones</a>: Clorindione</li>
<li><a href="Diphenadione.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenadione" title="Diphenadione">Diphenadione</a></li>
<li><a href="Phenindione.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenindione" title="Phenindione">Phenindione</a></li>
<li>Other: Tioclomarol</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Factor Xa inhibitors<br>(with some II inhibition)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">Heparin</a> group/<br>glycosaminoglycans/<br>(bind antithrombin)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Low-molecular-weight heparin
<ul><li>Bemiparin</li>
<li>Certoparin</li>
<li><a href="Dalteparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Dalteparin_sodium" title="Dalteparin sodium">Dalteparin</a></li>
<li><a href="Enoxaparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Enoxaparin_sodium" title="Enoxaparin sodium">Enoxaparin</a></li>
<li>Nadroparin</li>
<li>Parnaparin</li>
<li>Reviparin</li>
<li>Tinzaparin</li></ul></li>
<li>Oligosaccharides
<ul><li><a href="Fondaparinux.htm" tppabs="https://ptable.com/wiki/compounds/A/Fondaparinux" title="Fondaparinux">Fondaparinux</a></li>
<li>Idraparinux<sup>§</sup></li></ul></li>
<li>Heparinoids
<ul><li>Danaparoid</li>
<li><a href="Dermatan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dermatan_sulfate" title="Dermatan sulfate">Dermatan sulfate</a></li>
<li>Sulodexide</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Direct Xa inhibitors ("xabans")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Apixaban</li>
<li>Betrixaban</li>
<li>Darexaban<sup>§</sup></li>
<li>Edoxaban</li>
<li>Otamixaban<sup>§</sup></li>
<li>Rivaroxaban</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Direct thrombin (IIa) inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bivalent: Hirudin
<ul><li><a href="Bivalirudin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bivalirudin" title="Bivalirudin">Bivalirudin</a></li>
<li>Desirudin</li>
<li><a href="Lepirudin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lepirudin" title="Lepirudin">Lepirudin</a></li></ul></li>
<li>Univalent: <a href="Argatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Argatroban" title="Argatroban">Argatroban</a></li>
<li>Dabigatran</li>
<li><span class="new">Efegatran</span></li>
<li>Inogatran<sup>§</sup></li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Melagatran" title="Melagatran" class="mw-redirect">Melagatran</a><sup>‡</sup></li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Ximelagatran" title="Ximelagatran">Ximelagatran</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antithrombin III</li>
<li>Defibrotide</li>
<li>Protein C
<ul><li><a href="Drotrecogin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Drotrecogin_alfa" title="Drotrecogin alfa">Drotrecogin alfa</a><sup>‡</sup></li></ul></li>
<li><a href="Ramatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramatroban" title="Ramatroban">Ramatroban</a></li>
<li>REG1</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thrombolytic drugs/<br>fibrinolytics</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Plasminogen activators: r-tPA
<ul><li>Alteplase</li>
<li><a href="Reteplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Reteplase" title="Reteplase">Reteplase</a></li>
<li><a href="Tenecteplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Tenecteplase" title="Tenecteplase">Tenecteplase</a></li>
<li>Desmoteplase<sup>†</sup></li></ul></li>
<li>UPA
<ul><li>Saruplase</li>
<li><a href="Urokinase.htm" tppabs="https://ptable.com/wiki/compounds/A/Urokinase" title="Urokinase">Urokinase</a></li></ul></li>
<li><a href="Anistreplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Anistreplase" title="Anistreplase">Anistreplase</a></li>
<li>Monteplase</li>
<li><a href="Streptokinase.htm" tppabs="https://ptable.com/wiki/compounds/A/Streptokinase" title="Streptokinase">Streptokinase</a><sup>#</sup></li>
<li>Other serine endopeptidases: Ancrod</li>
<li>Brinase</li>
<li>Fibrinolysin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-medicinal</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Citrate</li>
<li><a href="Ethylenediaminetetraacetic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylenediaminetetraacetic_acid" title="Ethylenediaminetetraacetic acid">EDTA</a></li>
<li><a href="Oxalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxalate" title="Oxalate">Oxalate</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Pest_control:_Rodenticides" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Pest_control:_Rodenticides" style="font-size:114%;margin:0 4em">Pest control: Rodenticides</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;;line-height:1.2em;">Anticoagulants /<br>Vitamin K antagonists</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;line-height:1.2em;font-weight:normal;"><a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">Coumarins</a> /<br><a href="4-Hydroxycoumarins.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Hydroxycoumarins" title="4-Hydroxycoumarins">4-Hydroxycoumarins</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;line-height:1.2em;font-weight:normal;font-size:smaller;">1st generation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">Warfarin</a></li>
<li><a href="Coumatetralyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumatetralyl" title="Coumatetralyl">Coumatetralyl</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;line-height:1.2em;font-weight:normal;font-size:smaller;">2nd generation (Superwarfarins)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Brodifacoum.htm" tppabs="https://ptable.com/wiki/compounds/A/Brodifacoum" title="Brodifacoum">Brodifacoum</a></li>
<li><a href="Bromadiolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromadiolone" title="Bromadiolone">Bromadiolone</a></li>
<li><a href="Difenacoum.htm" tppabs="https://ptable.com/wiki/compounds/A/Difenacoum" title="Difenacoum">Difenacoum</a></li>
<li><a href="Flocoumafen.htm" tppabs="https://ptable.com/wiki/compounds/A/Flocoumafen" title="Flocoumafen">Flocoumafen</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;line-height:1.2em;font-weight:normal;"><a href="1,3-Indandione.htm" tppabs="https://ptable.com/wiki/compounds/A/1%2C3-Indandione" title="1,3-Indandione">1,3-Indandiones</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Chlorophacinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorophacinone" title="Chlorophacinone">Chlorophacinone</a></li>
<li><a href="Pindone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pindone" title="Pindone">Pindone</a></li>
<li><a href="Diphenadione.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphacinone" title="Diphacinone" class="mw-redirect">Diphacinone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;line-height:1.2em;font-weight:normal;">Others</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Difethialone</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;">Convulsants</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Crimidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Crimidine" title="Crimidine">Crimidine</a></li>
<li>Phenylsilatrane</li>
<li><a href="Strychnine.htm" tppabs="https://ptable.com/wiki/compounds/A/Strychnine" title="Strychnine">Strychnine</a></li>
<li>Tetramethylenedisulfotetramine</li>
<li>Chlorophenylsilatrane</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;"><a href="Vitamin_D.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_D" title="Vitamin D">Calciferols</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Cholecalciferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cholecalciferol" title="Cholecalciferol">Cholecalciferol</a></li>
<li><a href="Ergocalciferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ergocalciferol" title="Ergocalciferol">Ergocalciferol</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;">Inorganic compounds</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aluminium_phosphide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aluminium_phosphide" title="Aluminium phosphide">Aluminium phosphide</a></li>
<li><a href="Arsenic.htm" tppabs="https://ptable.com/wiki/compounds/A/Arsenic" title="Arsenic">Arsenic</a></li>
<li><a href="Barium_carbonate.htm" tppabs="https://ptable.com/wiki/compounds/A/Barium_carbonate" title="Barium carbonate">Barium carbonate</a></li>
<li><a href="Calcium_phosphide.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium_phosphide" title="Calcium phosphide">Calcium phosphide</a></li>
<li>Cyanide</li>
<li><a href="Thallium(I)_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Thallium(I)_sulfate" title="Thallium(I) sulfate">Thallium sulfate</a></li>
<li>Zinc phosphide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;">Organochlorine</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Chloralose.htm" tppabs="https://ptable.com/wiki/compounds/A/Chloralose" title="Chloralose">Chloralose</a></li>
<li><a href="Endrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Endrin" title="Endrin">Endrin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;">Organophosphorus</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Phosacetim</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;">Respiratory toxins</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Bromethalin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromethalin" title="Bromethalin">Bromethalin</a></li>
<li><a href="Fluoroacetamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoroacetamide" title="Fluoroacetamide">Fluoroacetamide</a></li>
<li>1,3-Difluoro-2-propanol (Gliftor)</li>
<li><a href="Sodium_fluoroacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium_fluoroacetate" title="Sodium fluoroacetate">Sodium fluoroacetate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;background:powderblue;">Others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>α-Naphthylthiourea</li>
<li><a href="Norbormide.htm" tppabs="https://ptable.com/wiki/compounds/A/Norbormide" title="Norbormide">Norbormide</a></li>
<li><a href="Pyrinuron.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrinuron" title="Pyrinuron">Pyrinuron</a></li>
<li>Scilliroside</li>
<li>Flupropadine</li></ul>
</div></td></tr></tbody></table></div>










<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2014-01-21" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Coumadin&oldid=591782843  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Coumadin&oldid=591782843'" tppabs="https://en.wikipedia.org/wiki/?title=Coumadin&oldid=591782843">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>



</body></html>